Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	actin binding	MAP1A MYO9A TRPC6 EPS8L1 TWF1 SPTBN5 WIPF2 VCL EVL SPEF1 ACTR3B SHROOM2 FAM107A XIRP2 MICAL2 TMOD1 TNS4	3.80e-06	479	191	17	GO:0003779
GeneOntologyMolecularFunction	cytoskeletal protein binding	LARP6 MAP1A CENPF MYO9A TRPC6 EPS8L1 CLIP1 TWF1 SPTBN5 DES KCNA5 KIF14 WIPF2 VCL RAD51D EVL SPEF1 RPH3AL ACTR3B SHROOM2 KIF7 FAM107A XIRP2 MICAL2 TMOD1 TNS4 KIF1C	6.31e-06	1099	191	27	GO:0008092
GeneOntologyMolecularFunction	cysteine-type deubiquitinase activity	USP34 USP17L1 USP17L18 USP17L3 OTUD3 USP3 USP37 USP54	1.40e-05	114	191	8	GO:0004843
GeneOntologyMolecularFunction	deubiquitinase activity	USP34 USP17L1 USP17L18 USP17L3 OTUD3 USP3 USP37 USP54	2.59e-05	124	191	8	GO:0101005
GeneOntologyMolecularFunction	ubiquitin-like protein peptidase activity	USP34 USP17L1 USP17L18 USP17L3 OTUD3 USP3 USP37 USP54	5.28e-05	137	191	8	GO:0019783
GeneOntologyMolecularFunction	cysteine-type peptidase activity	USP34 USP17L1 USP17L18 USP17L3 OTUD3 USP3 USP37 USP54 ESPL1	9.98e-05	192	191	9	GO:0008234
GeneOntologyMolecularFunction	arylsulfatase activity	ARSK SULF1 STS	2.90e-04	14	191	3	GO:0004065
GeneOntologyMolecularFunction	sulfuric ester hydrolase activity	ARSK SULF1 STS	5.31e-04	17	191	3	GO:0008484
GeneOntologyMolecularFunction	microtubule motor activity	KIF14 DNAH8 DNAH10 KIF7 KIF1C	5.56e-04	70	191	5	GO:0003777
GeneOntologyBiologicalProcess	protein deubiquitination	USP34 USP17L1 USP17L18 USP17L3 OTUD3 USP3 SHMT2 USP37 USP54	2.02e-06	125	186	9	GO:0016579
GeneOntologyBiologicalProcess	protein depolymerization	MAP1A TWF1 SPTBN5 KIF14 EVL SPEF1 SHROOM2 MICAL2 TMOD1	6.49e-06	144	186	9	GO:0051261
GeneOntologyBiologicalProcess	protein modification by small protein removal	USP34 USP17L1 USP17L18 USP17L3 OTUD3 USP3 SHMT2 USP37 USP54	6.49e-06	144	186	9	GO:0070646
GeneOntologyBiologicalProcess	negative regulation of protein depolymerization	MAP1A TWF1 SPTBN5 EVL SPEF1 SHROOM2 TMOD1	1.60e-05	89	186	7	GO:1901880
GeneOntologyBiologicalProcess	actin filament depolymerization	TWF1 SPTBN5 EVL SHROOM2 MICAL2 TMOD1	2.88e-05	66	186	6	GO:0030042
GeneOntologyBiologicalProcess	negative regulation of protein-containing complex disassembly	MAP1A TWF1 SPTBN5 EVL SPEF1 SHROOM2 TMOD1	3.42e-05	100	186	7	GO:0043242
GeneOntologyBiologicalProcess	regulation of protein depolymerization	MAP1A TWF1 SPTBN5 EVL SPEF1 SHROOM2 TMOD1	4.68e-05	105	186	7	GO:1901879
GeneOntologyBiologicalProcess	regulation of protein-containing complex disassembly	MAP1A INSR TWF1 SPTBN5 EVL SPEF1 SHROOM2 TMOD1	4.98e-05	144	186	8	GO:0043244
GeneOntologyBiologicalProcess	negative regulation of actin filament depolymerization	TWF1 SPTBN5 EVL SHROOM2 TMOD1	1.04e-04	52	186	5	GO:0030835
Domain	UCH	USP34 USP17L1 USP17L18 USP17L3 USP3 USP37 USP54	8.30e-06	71	192	7	PF00443
Domain	USP_2	USP34 USP17L1 USP17L18 USP17L3 USP3 USP37 USP54	8.30e-06	71	192	7	PS00973
Domain	USP_3	USP34 USP17L1 USP17L18 USP17L3 USP3 USP37 USP54	9.11e-06	72	192	7	PS50235
Domain	USP_dom	USP34 USP17L1 USP17L18 USP17L3 USP3 USP37 USP54	9.11e-06	72	192	7	IPR028889
Domain	Peptidase_C19_UCH	USP34 USP17L1 USP17L18 USP17L3 USP3 USP37 USP54	9.11e-06	72	192	7	IPR001394
Domain	TRPC_channel	TRPC6 TRPM2 TRPC7	3.63e-05	7	192	3	IPR002153
Domain	PTB	EPS8L1 TNS3 TNS4	5.77e-05	8	192	3	IPR013625
Domain	PTB	EPS8L1 TNS3 TNS4	5.77e-05	8	192	3	PF08416
Domain	USP_CS	USP34 USP17L1 USP17L18 USP17L3 USP3 USP37	5.94e-05	66	192	6	IPR018200
Domain	USP_1	USP34 USP17L18 USP17L3 USP3 USP37 USP54	8.29e-05	70	192	6	PS00972
Domain	PDZ	PTPN13 PDZD4 MPP3 DVL3 PARD3B SHROOM2 MAST3 AHNAK2	1.06e-04	141	192	8	PF00595
Domain	PDZ	PTPN13 PDZD4 MPP3 DVL3 PARD3B SHROOM2 MAST3 AHNAK2	1.49e-04	148	192	8	SM00228
Domain	-	PTPN13 PDZD4 MPP3 DVL3 PARD3B SHROOM2 MAST3 AHNAK2	1.63e-04	150	192	8	2.30.42.10
Domain	PDZ	PTPN13 PDZD4 MPP3 DVL3 PARD3B SHROOM2 MAST3 AHNAK2	1.71e-04	151	192	8	PS50106
Domain	PDZ	PTPN13 PDZD4 MPP3 DVL3 PARD3B SHROOM2 MAST3 AHNAK2	1.79e-04	152	192	8	IPR001478
Domain	Alkaline_phosphatase_core	ARSK SULF1 PIGO STS	2.74e-04	31	192	4	IPR017850
Domain	Alkaline_Pase-like_a/b/a	ARSK SULF1 PIGO STS	2.74e-04	31	192	4	IPR017849
Domain	-	ARSK SULF1 PIGO STS	2.74e-04	31	192	4	3.40.720.10
Domain	GRIN_C	GPRIN1 GPRIN2	3.13e-04	3	192	2	PF15235
Domain	GRIN_C	GPRIN1 GPRIN2	3.13e-04	3	192	2	IPR032745
Domain	PH_dom-like	PSD TRIO EPS8L1 PLEKHG5 SPTBN5 PTPN13 PLEKHA7 TNS3 PHLDB3 EVL ARHGEF28 ASAP3 TNS4	4.81e-04	426	192	13	IPR011993
Domain	HABP4_PAI-RBP1	USP17L18 USP17L3 HABP4	5.43e-04	16	192	3	PF04774
Domain	HABP4_PAIRBP1-bd	USP17L18 USP17L3 HABP4	5.43e-04	16	192	3	IPR006861
Domain	G2F	HMCN2 HMCN1	6.22e-04	4	192	2	PF07474
Domain	Tensin_PTB	TNS3 TNS4	6.22e-04	4	192	2	IPR033929
Domain	NIDOGEN_G2	HMCN2 HMCN1	6.22e-04	4	192	2	PS50993
Domain	GFP	HMCN2 HMCN1	6.22e-04	4	192	2	IPR009017
Domain	G2_nidogen/fibulin_G2F	HMCN2 HMCN1	6.22e-04	4	192	2	IPR006605
Domain	SULFATASE_1	ARSK SULF1 STS	6.54e-04	17	192	3	PS00523
Domain	SULFATASE_2	ARSK SULF1 STS	6.54e-04	17	192	3	PS00149
Domain	-	PSD TRIO PLEKHG5 SPTBN5 PTPN13 PLEKHA7 TNS3 PHLDB3 EVL ARHGEF28 ASAP3 TNS4	7.53e-04	391	192	12	2.30.29.30
Domain	Sulfatase	ARSK SULF1 STS	7.79e-04	18	192	3	PF00884
Domain	Sulfatase_N	ARSK SULF1 STS	7.79e-04	18	192	3	IPR000917
Domain	SAPAP	DLGAP3 DLGAP4	1.03e-03	5	192	2	IPR005026
Domain	GKAP	DLGAP3 DLGAP4	1.03e-03	5	192	2	PF03359
Domain	TRP_2	TRPC6 TRPC7	1.53e-03	6	192	2	PF08344
Domain	ADEAMc	ADAD2 ADAT1	1.53e-03	6	192	2	SM00552
Domain	Kinesin_assoc	KIF14 KIF1C	1.53e-03	6	192	2	PF16183
Domain	A_deamin	ADAD2 ADAT1	1.53e-03	6	192	2	PF02137
Domain	A_DEAMIN_EDITASE	ADAD2 ADAT1	1.53e-03	6	192	2	PS50141
Domain	TRP_dom	TRPC6 TRPC7	1.53e-03	6	192	2	IPR013555
Domain	Kinesin_assoc	KIF14 KIF1C	1.53e-03	6	192	2	IPR032405
Domain	A_deamin	ADAD2 ADAT1	1.53e-03	6	192	2	IPR002466
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	CCDC8 TRIO MYO9A SPATA18 C19orf47 N4BP3 PPM1H LUZP1 TWF1 PTPN13 SUPT4H1 KIF14 PLEKHA7 TNS3 RBM15 ARHGEF28 PARP8 PARD3B SAMD11 USP54 PRRC1 AHNAK2 KIF1C	7.20e-10	861	195	23	36931259
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	USP34 TRIO SPEG C19orf47 MCM5 STK11IP PLEKHG5 PRR12 ZNF296 PLXNA1 MPP3 PHLDB3 POLE POLG UBE3B ZNF316 FBXL19 C2CD2 C8orf58 PKMYT1 CELSR2 MTMR14 ESPL1 ADAT1 AHNAK2 HR	7.62e-10	1105	195	26	35748872
Pubmed	LncRNAs-directed PTEN enzymatic switch governs epithelial-mesenchymal transition.	TOPAZ1 SPATA18 LUZP1 PTPN13 ADAMTS15 DNAH10 LYRM1 XPC MICAL2	4.99e-07	168	195	9	30631154
Pubmed	Chr21 protein-protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer's disease.	HDAC9 USP34 LARP6 STAG1 TRIO HLCS PTPN13 SULF1 GPSM2 PRRC2A SUPT20H POLG DVL3 XPC ACTR3B SHROOM2 ZNF34 MICAL2 MRPS9 YY1AP1 USP54 LRRFIP1	3.64e-06	1285	195	22	35914814
Pubmed	Impaired plasma membrane localization of ubiquitin ligase complex underlies 3-M syndrome development.	CCDC8 MAP1A EXOSC5 LUZP1 TWF1 SPTBN5 KIF14 PRRC2A RBM15 DVL3 MRPS9 CHTOP KIF1C	5.16e-06	496	195	13	31343991
Pubmed	KCTD13-mediated ubiquitination and degradation of GluN1 regulates excitatory synaptic transmission and seizure susceptibility.	HK1 MAP1A TRIO MYO9A PLEKHG5 LUZP1 TWF1 TOMM70 DLGAP3 PLEKHA7 PRRC2A VCL EVL DLGAP4 ACTR3B PPFIA3 SHROOM2 MICAL2 MRPS9 TMOD1 USP54 RPL8 LRRFIP1	6.08e-06	1431	195	23	37142655
Pubmed	The E3 ubiquitin ligase HECTD1 contributes to cell proliferation through an effect on mitosis.	CCDC8 CENPF C19orf47 ABT1 SGO2 PRRC2A TICRR RBM15 POLE SRBD1 NOP14 TMOD1 ESPL1 CHTOP RPL8 LRRFIP1	6.74e-06	759	195	16	35915203
Pubmed	Comprehensive identification of phosphorylation sites in postsynaptic density preparations.	MAP1A SPEG GPRIN1 LUZP1 PRRC2A DLGAP4 PPFIA3 RPL8 MAST3	6.88e-06	231	195	9	16452087
Pubmed	In-Depth In Vivo Crosslinking in Minutes by a Compact, Membrane-Permeable, and Alkynyl-Enrichable Crosslinker.	HK1 LARP6 STAG1 CENPF MCM5 LUZP1 EHD4 DES TCHHL1 OTUD3 DNAH8 EVL DR1 ZNF789 PCDHGA6 PARP8 KHDRBS2 XPC SRBD1 NOP14 STS ABCB9 MRPS9	6.89e-06	1442	195	23	35575683
Pubmed	Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function.	HK1 MYO9A MCM5 LUZP1 EHD4 USP3 VCL TNS3 PHLDB3 RBM15 POLE SHMT2 CHD7 XPC SRBD1 NOP14 BAZ2A MICAL2 SNRPA1 CHTOP RPL8 AHNAK2	8.21e-06	1353	195	22	29467282
Pubmed	Subunit composition of mammalian transient receptor potential channels in living cells.	TRPC6 TRPM2 TRPC7	9.52e-06	8	195	3	12032305
Pubmed	The RNA-mediated estrogen receptor α interactome of hormone-dependent human breast cancer cell nuclei.	MRM1 MCM5 EXOSC5 N4BP3 GGCX LUZP1 TWF1 PRR12 TOMM70 PTPN13 KIF14 PLEKHA7 PRRC2A SUPT20H FLYWCH1 CHD7 XPC SRBD1 HABP4 NOP14 BAZ2A ZFHX3 CHTOP	1.25e-05	1497	195	23	31527615
Pubmed	Identification of common binding sites for calmodulin and inositol 1,4,5-trisphosphate receptors on the carboxyl termini of trp channels.	TRPC6 TRPM2 TRPC7	1.42e-05	9	195	3	11290752
Pubmed	Systematic bromodomain protein screens identify homologous recombination and R-loop suppression pathways involved in genome integrity.	USP34 PSD MAP1A HLCS GGCX LUZP1 HMCN2 SUPT4H1 HPN SUPT20H ZNF316 XPC PPFIA3 KIF7 ZFHX4 BAZ2A ZFHX3 USP54 CHTOP	1.88e-05	1116	195	19	31753913
Pubmed	Discovery and Characterization of ZUFSP/ZUP1, a Distinct Deubiquitinase Class Important for Genome Stability.	USP34 OTUD3 USP3 POLE USP37 KIF7 USP54	2.05e-05	147	195	7	29576527
Pubmed	Interactomes of Glycogen Synthase Kinase-3 Isoforms.	MAP1A TRIO MYO9A LUZP1 PTPN13 FBXO42 VCL TNS3	2.55e-05	209	195	8	36779422
Pubmed	FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia.	BDP1 CENPF TOPAZ1 SPEG MRM1 GPRIN1 KRBA1 RBM15 SUPT20H MON1A XIRP2 CHTOP	2.68e-05	497	195	12	36774506
Pubmed	Phenotypic and Interaction Profiling of the Human Phosphatases Identifies Diverse Mitotic Regulators.	CCDC8 TRIO GPRIN1 PPM1H LUZP1 EHD4 TOMM70 PTPN13 KIF14 PLEKHA7 PRRC2A TNS3 RBM15 SHMT2 PPFIA3 KIF7 NOP14 MTMR14	2.84e-05	1049	195	18	27880917
Pubmed	Siglec-5 and Siglec-14 are polymorphic paired receptors that modulate neutrophil and amnion signaling responses to group B Streptococcus.	SIGLEC5 SIGLEC14	3.13e-05	2	195	2	24799499
Pubmed	Circuit-selective striatal synaptic dysfunction in the Sapap3 knockout mouse model of obsessive-compulsive disorder.	DLGAP3 DLGAP4	3.13e-05	2	195	2	23414593
Pubmed	A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration.	TNS3 TNS4	3.13e-05	2	195	2	17643115
Pubmed	Mature middle and inner ears express Chd7 and exhibit distinctive pathologies in a mouse model of CHARGE syndrome.	CDH23 CHD7	3.13e-05	2	195	2	21875659
Pubmed	EHD4 and CDH23 are interacting partners in cochlear hair cells.	CDH23 EHD4	3.13e-05	2	195	2	19487694
Pubmed	Nociceptive transient receptor potential canonical 7 (TRPC7) mediates aging-associated tumorigenesis induced by ultraviolet B.	TRPM2 TRPC7	3.13e-05	2	195	2	31755176
Pubmed	The mouse ZFH-4 protein contains four homeodomains and twenty-two zinc fingers.	ZFHX4 ZFHX3	3.13e-05	2	195	2	10873665
Pubmed	Molecular determinants for cardiovascular TRPC6 channel regulation by Ca2+/calmodulin-dependent kinase II.	TRPC6 TRPC7	3.13e-05	2	195	2	23529130
Pubmed	Immunomodulatory activity of extracellular Hsp70 mediated via paired receptors Siglec-5 and Siglec-14.	SIGLEC5 SIGLEC14	3.13e-05	2	195	2	26459514
Pubmed	DRR drives brain cancer invasion by regulating cytoskeletal-focal adhesion dynamics.	MAP1A FAM107A	3.13e-05	2	195	2	20543869
Pubmed	PLC-mediated PI(4,5)P2 hydrolysis regulates activation and inactivation of TRPC6/7 channels.	TRPC6 TRPC7	3.13e-05	2	195	2	24470487
Pubmed	Expression profile of the transient receptor potential (TRP) family in neutrophil granulocytes: evidence for currents through long TRP channel 2 induced by ADP-ribose and NAD.	TRPC6 TRPM2	3.13e-05	2	195	2	12564954
Pubmed	Mammalian hemicentin 1 is assembled into tracks in the extracellular matrix of multiple tissues.	HMCN2 HMCN1	3.13e-05	2	195	2	32035013
Pubmed	The human desmin locus: gene organization and LCR-mediated transcriptional control.	SPEG DES	3.13e-05	2	195	2	16545539
Pubmed	An internal EELD domain facilitates mitochondrial targeting of Mcl-1 via a Tom70-dependent pathway.	MCL1 TOMM70	3.13e-05	2	195	2	16822835
Pubmed	HB-EGF is associated with DNA damage and Mcl-1 turnover in human glioma cell lines treated by Temozolomide.	MCL1 HBEGF	3.13e-05	2	195	2	28970067
Pubmed	Protein interaction network of the mammalian Hippo pathway reveals mechanisms of kinase-phosphatase interactions.	CLIP1 PPM1H LUZP1 PTPN13 KIF14 PLEKHA7 RBM15 PARP8 KIF7 USP54 KIF1C	4.82e-05	446	195	11	24255178
Pubmed	A germline-specific class of small RNAs binds mammalian Piwi proteins.	SOCS7 WIPF2 PRRC2A PIGO RAD51D POLG UBE3B DLGAP4 C8orf58 ABCB9 MAST3	5.22e-05	450	195	11	16751776
Pubmed	DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity.	USP34 STAG1 CENPF EXOSC5 LUZP1 PRR12 SGO2 USP3 FLYWCH1 POLE ZNF316	5.54e-05	453	195	11	29656893
Pubmed	A Degradation Motif in STAU1 Defines a Novel Family of Proteins Involved in Inflammation.	MAP1A ABT1 EXOSC5 LUZP1 PTPN13 PRRC2A VCL TNS3 DVL3 XPC THOC5 ESPL1 LRRFIP1 AHNAK2	6.51e-05	724	195	14	36232890
Pubmed	An antibody-based proximity labeling map reveals mechanisms of SARS-CoV-2 inhibition of antiviral immunity.	USP34 TRIO HLCS GGCX KIF14 VCL TNS3 PHLDB3 DR1 CHD7 USP54 ESPL1 CHTOP PRRC1	7.42e-05	733	195	14	34672954
Pubmed	Neuron-specific protein network mapping of autism risk genes identifies shared biological mechanisms and disease-relevant pathologies.	MAP1A TRIO TSPOAP1 GPRIN1 DLGAP3 EVL DLGAP4 DVL3 ACTR3B PPFIA3 SHROOM2 CELSR2 CNTNAP2 MRPS9 SNRPA1 CHTOP RPL8 LRRFIP1	8.16e-05	1139	195	18	36417873
Pubmed	Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription.	USP34 HK1 CENPF MCM5 KIF14 PRRC2A VCL RBM15 POLE CHD7 NOP14 BAZ2A RPL8	8.93e-05	653	195	13	22586326
Pubmed	Distribution and evolution of von Willebrand/integrin A domains: widely dispersed domains with roles in cell adhesion and elsewhere.	HMCN2 HMCN1	9.35e-05	3	195	2	12388743
Pubmed	Cloning and characterization of a novel mouse Siglec, mSiglec-F: differential evolution of the mouse and human (CD33) Siglec-3-related gene clusters.	SIGLEC5 SIGLEC14	9.35e-05	3	195	2	11579105
Pubmed	Selective association of TRPC channel subunits in rat brain synaptosomes.	TRPC6 TRPM2	9.35e-05	3	195	2	12377790
Pubmed	Mast Cell-Specific Expression of Human Siglec-8 in Conditional Knock-in Mice.	SIGLEC5 SIGLEC14	9.35e-05	3	195	2	30577572
Pubmed	A novel Siglec-F+ neutrophil subset in the mouse nasal mucosa exhibits an activated phenotype and is increased in an allergic rhinitis model.	SIGLEC5 SIGLEC14	9.35e-05	3	195	2	32247614
Pubmed	Major contribution of the 3/6/7 class of TRPC channels to myocardial ischemia/reperfusion and cellular hypoxia/reoxygenation injuries.	TRPC6 TRPC7	9.35e-05	3	195	2	28526717
Pubmed	Identification and biochemical analysis of GRIN1 and GRIN2.	GPRIN1 GPRIN2	9.35e-05	3	195	2	15488195
Pubmed	The Retinal Basis of Light Aversion in Neonatal Mice.	TRPC6 TRPC7	9.35e-05	3	195	2	35396331
Pubmed	Endogenous airway mucins carry glycans that bind Siglec-F and induce eosinophil apoptosis.	SIGLEC5 SIGLEC14	9.35e-05	3	195	2	25497369
Pubmed	A secreted protein promotes cleavage furrow maturation during cytokinesis.	HMCN2 HMCN1	9.35e-05	3	195	2	21215633
Pubmed	Siglec-F-dependent negative regulation of allergen-induced eosinophilia depends critically on the experimental model.	SIGLEC5 SIGLEC14	9.35e-05	3	195	2	24698729
Pubmed	Discovery of Siglec-14, a novel sialic acid receptor undergoing concerted evolution with Siglec-5 in primates.	SIGLEC5 SIGLEC14	9.35e-05	3	195	2	17012248
Pubmed	Siglec-F is induced by granulocyte-macrophage colony-stimulating factor and enhances interleukin-4-induced expression of arginase-1 in mouse macrophages.	SIGLEC5 SIGLEC14	9.35e-05	3	195	2	31520477
Pubmed	Antiallergic effect of anti-Siglec-F through reduction of eosinophilic inflammation in murine allergic rhinitis.	SIGLEC5 SIGLEC14	9.35e-05	3	195	2	23710953
Pubmed	Anti-Siglec-F antibody reduces allergen-induced eosinophilic inflammation and airway remodeling.	SIGLEC5 SIGLEC14	9.35e-05	3	195	2	19783675
Pubmed	Hemicentins assemble on diverse epithelia in the mouse.	HMCN2 HMCN1	9.35e-05	3	195	2	17015624
Pubmed	Frontline Science: Superior mouse eosinophil depletion in vivo targeting transgenic Siglec-8 instead of endogenous Siglec-F: Mechanisms and pitfalls.	SIGLEC5 SIGLEC14	9.35e-05	3	195	2	32134149
Pubmed	Siglec-F is a novel intestinal M cell marker.	SIGLEC5 SIGLEC14	9.35e-05	3	195	2	27524237
Pubmed	Human and mouse proteases: a comparative genomic approach.	USP34 USP17L1 USP17L3 USP3 USP37	9.55e-05	81	195	5	12838346
Pubmed	The human cytoplasmic dynein interactome reveals novel activators of motility.	TRIO HLCS MCM5 CLIP1 LUZP1 MVB12A KIF14 PLEKHA7 VCL SHMT2 PARD3B KIF7 MTMR14 USP54 KIF1C	1.03e-04	853	195	15	28718761
Pubmed	Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability.	BDP1 USP34 MAP1A MYO9A C19orf47 LUZP1 FBXO42 KIF14 RBM15 SUPT20H CHD7 YY1AP1	1.33e-04	588	195	12	38580884
Pubmed	Proximity-dependent biotin identification (BioID) reveals a dynamic LSD1-CoREST interactome during embryonic stem cell differentiation.	USP34 CENPF LUZP1 PRR12 PTPN13 KIF14 DVL3 CHD7 ZFHX4 ZFHX3	1.36e-04	418	195	10	34709266
Pubmed	A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2-Bispecific Antibody for Combination Cancer Therapy.	CCDC8 TRIO INSR GPRIN1 PTPN13 PLEKHA7 PHLDB3 DLGAP4 PARD3B CELSR2	1.45e-04	421	195	10	36976175
Pubmed	Gain of Additional BIRC3 Protein Functions through 3'-UTR-Mediated Protein Complex Formation.	HK1 TRIO CENPF SPATA18 MCM5 EHD4 TOMM70 KIF14 SGO2 PLEKHA7 PLXNA1 VCL RBM15 DNAH10 POLE SHMT2 MRPS9 SNRPA1 CHTOP RPL8	1.62e-04	1425	195	20	30948266
Pubmed	ATRX proximal protein associations boast roles beyond histone deposition.	CFDP1 FLYWCH1 XPC NOP14 ZFHX4	1.66e-04	91	195	5	34780483
Pubmed	Proteome-scale mapping of binding sites in the unstructured regions of the human proteome.	MAP1A TSPOAP1 PLEKHA7 ASAP3 CHD7 ARHGAP6 SLC12A1 XIRP2 PRRC1 LRRFIP1	1.71e-04	430	195	10	35044719
Pubmed	Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity.	SIGLEC5 SIGLEC14	1.86e-04	4	195	2	17562860
Pubmed	Defining the in vivo function of Siglec-F, a CD33-related Siglec expressed on mouse eosinophils.	SIGLEC5 SIGLEC14	1.86e-04	4	195	2	17272508
Pubmed	Multiple quantitative trait loci modify cochlear hair cell degeneration in the Beethoven (Tmc1Bth) mouse model of progressive hearing loss DFNA36.	MAP1A TMC2	1.86e-04	4	195	2	16648588
Pubmed	Deletion of SOCS7 leads to enhanced insulin action and enlarged islets of Langerhans.	INSR SOCS7	1.86e-04	4	195	2	16127460
Pubmed	Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors.	SIGLEC5 SIGLEC14	1.86e-04	4	195	2	19178537
Pubmed	Induction of Siglec-FhiCD101hi eosinophils in the lungs following murine hookworm Nippostrongylus brasiliensis infection.	SIGLEC5 SIGLEC14	1.86e-04	4	195	2	37251384
Pubmed	Melanopsin Phototransduction Is Repurposed by ipRGC Subtypes to Shape the Function of Distinct Visual Circuits.	TRPC6 TRPC7	1.86e-04	4	195	2	30017393
Pubmed	Critical Roles of Xirp Proteins in Cardiac Conduction and Their Rare Variants Identified in Sudden Unexplained Nocturnal Death Syndrome and Brugada Syndrome in Chinese Han Population.	KCNA5 XIRP2	1.86e-04	4	195	2	29306897
Pubmed	Tensin3 is a negative regulator of cell migration and all four Tensin family members are downregulated in human kidney cancer.	TNS3 TNS4	1.86e-04	4	195	2	19194507
Pubmed	Vertebrate extracellular matrix protein hemicentin-1 interacts physically and genetically with basement membrane protein nidogen-2.	HMCN2 HMCN1	1.86e-04	4	195	2	36007682
Pubmed	Phosphoproteomics identifies microglial Siglec-F inflammatory response during neurodegeneration.	SIGLEC5 SIGLEC14	1.86e-04	4	195	2	33289969
Pubmed	Behavioral abnormalities observed in Zfhx2-deficient mice.	ZFHX4 ZFHX3	1.86e-04	4	195	2	23300874
Pubmed	Sensory transduction is required for normal development and maturation of cochlear inner hair cell synapses.	CDH23 TMC2	1.86e-04	4	195	2	34734805
Pubmed	IL-17 mediates protective immunity against nasal infection with Bordetella pertussis by mobilizing neutrophils, especially Siglec-F+ neutrophils.	SIGLEC5 SIGLEC14	1.86e-04	4	195	2	33976385
Pubmed	Securin-independent regulation of separase by checkpoint-induced shugoshin-MAD2.	SGO2 ESPL1	1.86e-04	4	195	2	32322060
Pubmed	Hemicentin-1 is an essential extracellular matrix component of the dermal-epidermal and myotendinous junctions.	HMCN2 HMCN1	1.86e-04	4	195	2	34504132
Pubmed	DUB-1, a deubiquitinating enzyme with growth-suppressing activity.	USP17L1 USP17L18 USP17L3	2.14e-04	21	195	3	8622927
Pubmed	DUB-1A, a novel deubiquitinating enzyme subfamily member, is polyubiquitinated and cytokine-inducible in B-lymphocytes.	USP17L1 USP17L18 USP17L3	2.14e-04	21	195	3	14583620
Pubmed	DUB-2A, a new member of the DUB subfamily of hematopoietic deubiquitinating enzymes.	USP17L1 USP17L18 USP17L3	2.14e-04	21	195	3	11468161
Pubmed	The murine DUB-1 gene is specifically induced by the betac subunit of interleukin-3 receptor.	USP17L1 USP17L18 USP17L3	2.14e-04	21	195	3	8756639
Pubmed	Lymphocyte-specific murine deubiquitinating enzymes induced by cytokines.	USP17L1 USP17L18 USP17L3	2.14e-04	21	195	3	12447969
Pubmed	DUB-1, a fate determinant of dynein heavy chain in B-lymphocytes, is regulated by the ubiquitin-proteasome pathway.	USP17L1 USP17L18 USP17L3	2.14e-04	21	195	3	18980247
Pubmed	SR protein kinases promote splicing of nonconsensus introns.	CDH23 EPS8L1 GGCX HMCN2 KIF14 PRRC2A TNS3 RBM15 ZFHX4	2.18e-04	361	195	9	26167880
Pubmed	Cullin 1 (CUL1) Promotes Primary Ciliogenesis through the Induction of Ubiquitin-Proteasome-Dependent Dvl2 Degradation.	CCDC8 CDH23 DLGAP4 HMCN1 ZNF333 ESPL1	2.26e-04	152	195	6	34299191
Pubmed	JAK2 is required for induction of the murine DUB-1 gene.	USP17L1 USP17L18 USP17L3	2.47e-04	22	195	3	9154835
Pubmed	Prediction of the coding sequences of unidentified human genes. XI. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro.	HDAC9 USP34 PLEKHG5 TOMM70 MICAL2	2.70e-04	101	195	5	9872452
Pubmed	Sequential genome-wide CRISPR-Cas9 screens identify genes regulating cell-surface expression of tetraspanins.	USP34 SPATA18 MCL1 DLGAP3 ZNF296 SLC41A3 PLEKHA7 TICRR KCNK13 FBXL19 THOC5 YY1AP1 ZNF333 AHNAK2	2.74e-04	832	195	14	36724073
Pubmed	Cloning and enzymatic analysis of 22 novel human ubiquitin-specific proteases.	USP34 USP37 USP54	2.83e-04	23	195	3	14715245
Pubmed	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.	BDP1 TRIO MYO9A TRPM2 INSR PPM1H PTPN13 SLC41A3 HPN FBXO42 USP3 EVL RPH3AL POLG PARD3B SHROOM2 C2CD2 ARHGAP6 MICAL2 ZFHX3	2.87e-04	1489	195	20	28611215
Pubmed	Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance.	MAP1A GPRIN1 CLIP1 VCL RNF34 USP54 LRRFIP1	3.03e-04	226	195	7	31452512
Pubmed	Characterization of expression of glycan ligands for Siglec-F in normal mouse lungs.	SIGLEC5 SIGLEC14	3.09e-04	5	195	2	20395633
Pubmed	Antisense RNA polymerase II divergent transcripts are P-TEFb dependent and substrates for the RNA exosome.	EXOSC5 SUPT4H1	3.09e-04	5	195	2	21670248
Pubmed	Differential mRNA expression and protein localization of the SAP90/PSD-95-associated proteins (SAPAPs) in the nervous system of the mouse.	DLGAP3 DLGAP4	3.09e-04	5	195	2	15024750
Interaction	YWHAG interactions	CCDC8 MYO9A SPEG SPATA18 C19orf47 MCM5 N4BP3 PLEKHG5 PPM1H LUZP1 TWF1 PTPN13 SUPT4H1 KIF14 PLEKHA7 VCL TNS3 TICRR RBM15 ARHGEF28 PARP8 PARD3B USP37 SHROOM2 KIF7 SAMD11 USP54 PRRC1 MAST3 AHNAK2 KIF1C	8.67e-07	1248	192	31	int:YWHAG
Interaction	YWHAH interactions	CCDC8 TRIO MYO9A SPEG SPATA18 C19orf47 N4BP3 PLEKHG5 PPM1H LUZP1 PTPN13 SUPT4H1 KIF14 PLEKHA7 VCL TNS3 TICRR RBM15 ARHGEF28 PARP8 PARD3B KIF7 SAMD11 USP54 PRRC1 MAST3 AHNAK2 KIF1C	2.04e-06	1102	192	28	int:YWHAH
Interaction	YWHAE interactions	HDAC9 CCDC8 MYO9A SPATA18 N4BP3 CLIP1 PLEKHG5 PPM1H LUZP1 DLGAP3 PTPN13 SUPT4H1 KIF14 PLEKHA7 PRRC2A VCL TICRR RBM15 ARHGEF28 PARP8 SHMT2 PARD3B SHROOM2 SAMD11 USP54 MAST3 GPRIN2 KIF1C	2.34e-05	1256	192	28	int:YWHAE
Interaction	LY6H interactions	ARSK INSR SULF1 PLXNA1 INHBE DVL3	2.48e-05	61	192	6	int:LY6H
Cytoband	12q24.3	CLIP1 POLE	2.69e-04	6	196	2	12q24.3
Cytoband	2q35	SPEG STK11IP DES USP37	3.77e-04	79	196	4	2q35
GeneFamily	PDZ domain containing	PTPN13 FRMPD2B PDZD4 MPP3 DVL3 PARD3B SHROOM2 MAST3 AHNAK2	1.10e-06	152	125	9	1220
GeneFamily	Sulfatases	ARSK SULF1 STS	2.44e-04	18	125	3	410
GeneFamily	Ubiquitin specific peptidases	USP34 USP3 USP37 USP54	6.06e-04	56	125	4	366
GeneFamily	SH2 domain containing	SOCS7 TXK SHE TNS3 TNS4	6.80e-04	101	125	5	741
GeneFamily	Transient receptor potential cation channels	TRPC6 TRPM2 TRPC7	9.31e-04	28	125	3	249
GeneFamily	Fibulins	HMCN2 HMCN1	1.29e-03	8	125	2	556
GeneFamily	Adenosine deaminases acting on RNA	ADAD2 ADAT1	1.29e-03	8	125	2	1303
GeneFamily	Kinesins\|Pleckstrin homology domain containing	KIF14 KIF7 KIF1C	3.94e-03	46	125	3	622
Coexpression	GSE27241_WT_VS_RORGT_KO_TH17_POLARIZED_CD4_TCELL_TREATED_WITH_DIGOXIN_UP	CHDH KIF14 TICRR POLE CHD7 USP37 CELSR2 BAZ2A ESPL1	8.67e-06	180	195	9	M8239
Coexpression	NAKAYA_B_CELL_FLUMIST_AGE_18_50YO_7DY_UP	TRIO TWF1 TOMM70 GPSM2 WIPF2 RAD51D UBE3B DLGAP4 KHDRBS2 SHMT2 SRBD1 CNTNAP2 TMOD1 MAST3	1.41e-05	475	195	14	M40979
Coexpression	LAZARO_GENETIC_MOUSE_MODEL_HIGH_GRADE_SMALL_CELL_NEUROENDOCRINE_LUNG_CARCINOMA_UP	HDAC9 PSD CENPF MCM5 GPRIN1 SOCS7 KIF14 SGO2 PDZD4 TICRR RBM15 POLE CHD7 PPFIA3 USP37 PKMYT1 CELSR2	1.44e-05	680	195	17	MM456
Coexpression	GSE2770_IL12_ACT_VS_ACT_CD4_TCELL_6H_UP	HK1 INSR TWF1 TEDC2 MON1A PIR PKMYT1 YY1AP1 RPL8	1.71e-05	196	195	9	M6063
Coexpression	GSE37534_UNTREATED_VS_ROSIGLITAZONE_TREATED_CD4_TCELL_PPARG1_AND_FOXP3_TRASDUCED_UP	INSR EXOSC5 DENND1C HPN KIF14 FGF9 OTUD3 ZFHX4 ZFHX3	1.78e-05	197	195	9	M8983
Coexpression	GSE30962_PRIMARY_VS_SECONDARY_ACUTE_LCMV_INF_CD8_TCELL_UP	CENPF MCM5 LUZP1 SGO2 TICRR SPEF1 POLE PKMYT1 ESPL1	2.01e-05	200	195	9	M5041
Coexpression	GSE13547_2H_VS_12_H_ANTI_IGM_STIM_BCELL_UP	CENPF EHD4 PTPN13 KIF14 GPSM2 SGO2 CHD7 MICAL2	5.44e-05	176	195	8	M2981
Coexpression	NAKAYAMA_SOFT_TISSUE_TUMORS_PCA2_UP	CENPF GPSM2 FGF9 MICAL2 ESPL1 AHNAK2	5.46e-05	89	195	6	M2761
ToppCell	severe-multiplets\|severe / disease stage, cell group and cell class	SPTBN5 KIF14 SGO2 RAD51D COL6A3 TEDC2 PIR TMEM121 NOP14	1.27e-07	183	196	9	78af8df48f0fe49ac37ccec0ad7b2993883b1148
ToppCell	Control-Endothelial-Endothelial-FOXM1\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CENPF KIF14 GPSM2 SGO2 TICRR POLE TEDC2 PKMYT1 ESPL1	1.67e-07	189	196	9	1e1499b062d9c647c8f38b0c4e0d871d159be5dd
ToppCell	droplet-Kidney-nan-21m-Epithelial-kidney_mesangial_cell\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MAP1A SPEG TRPC6 DES KCNA5 SULF1 C11orf96 KIF7 ZFHX3	1.75e-07	190	196	9	1803b1e7c36285f9eaabc3c6e9a9752c5908db3d
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	MYO9A PPM1H PTPN13 HPN PLEKHA7 ARHGEF28 PARD3B ARHGAP6 SLC12A1	2.18e-07	195	196	9	6477e6e7be5bd8eb99119a12ae16334ccddecd43
ToppCell	Brain_organoid-organoid_Tanaka_cellReport-5w-Neuronal-Intermediate\|5w / Sample Type, Dataset, Time_group, and Cell type.	TRIO INSR C11orf96 PDZD4 EVL CELSR2 ZFHX4 ZFHX3 MAST3	2.70e-07	200	196	9	c92e4fc0442404481fcac623d691dae6215b852d
ToppCell	Dividing_Macrophages-Cryobiopsy_01\|World / lung cells shred on cell class, cell subclass, sample id	CENPF KIF14 GPSM2 SGO2 TICRR ARHGEF28 PKMYT1 ESPL1	7.53e-07	166	196	8	c503036f3c19ef186e1e62c9643c49dea3827f51
ToppCell	Bac-SEP-Lymphocyte-T_NK-T_NK_proliferative\|Bac-SEP / Disease, Lineage and Cell Type	CENPF MCM5 KIF14 SGO2 TEDC2 BARX2 PKMYT1 TNS4	1.63e-06	184	196	8	848d05afd5a2ef61fb8a09c0f5fa2a56fd5c160b
ToppCell	droplet-Lung-21m-Hematologic-lymphocytic-Proliferating_T_cell-proliferating_T\|21m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	CENPF MCM5 KIF14 SGO2 FGF11 TICRR POLE PKMYT1	2.16e-06	191	196	8	15dbc5a03bfab8931c0fd385b0f25874736ae874
ToppCell	droplet-Lung-21m-Hematologic-lymphocytic-Proliferating_T_cell\|21m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	CENPF MCM5 KIF14 SGO2 FGF11 TICRR POLE PKMYT1	2.16e-06	191	196	8	45c15f5ce4a207ac944bed65d45f06c1657d1a6d
ToppCell	LPS_only-Endothelial-Endothelial-FOXM1\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CENPF KIF14 SGO2 TICRR POLE PKMYT1 ESPL1	2.20e-06	134	196	7	4d8f7ddad02fe76a614771e115ebb8e04623ba85
ToppCell	proximal-Hematologic-Platelet/Megakaryocyte\|proximal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	TRIO PPM1H TMEM81 SPTBN5 ANKDD1B PLEKHA7 FLYWCH1 TEDC2	2.24e-06	192	196	8	522d1bb15edf1d6006b80289bd3baadb99584ae8
ToppCell	proximal-3-Hematologic-Platelet/Megakaryocyte\|3 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	TRIO PPM1H TMEM81 SPTBN5 ANKDD1B PLEKHA7 FLYWCH1 TEDC2	2.24e-06	192	196	8	f5f83dec37dff32a0c471cb05d23d13b0b0ad0c9
ToppCell	proximal-Hematologic-Platelet/Megakaryocyte-3\|proximal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	TRIO PPM1H TMEM81 SPTBN5 ANKDD1B PLEKHA7 FLYWCH1 TEDC2	2.24e-06	192	196	8	57899a905ca3e336bb7f31edc6418a2546b9891a
ToppCell	E12.5-Mesenchymal-myocytic_cell\|E12.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	PSD SPEG EHD4 DES C11orf96 VCL COL6A3 ZFHX3	2.52e-06	195	196	8	aed243418cdb5df4563a7b935c1ecbd744590901
ToppCell	(1)_T_cells-(1)_T_cells_Dividing\|(1)_T_cells / Lung cell shreds - cell class (v4) and cell subclass (v4)	CENPF MCM5 KIF14 SGO2 TICRR TEDC2 PKMYT1 ESPL1	2.52e-06	195	196	8	cf00a0b4f341f0487d5b37810abe2952fdd3f6f2
ToppCell	E12.5-Mesenchymal-myocytic_cell-aortic_smooth_muscle_cell\|E12.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	PSD SPEG EHD4 DES C11orf96 VCL COL6A3 ZFHX3	2.52e-06	195	196	8	bff7685784688425bebd78b0f284a6d4475a9415
ToppCell	cycling_basal_cell\|World / shred by cell class for nasal brushing	CENPF MCM5 KIF14 GPSM2 SGO2 TICRR TEDC2 PKMYT1	2.61e-06	196	196	8	aa7bac70a2fe4a3cb28d89fa1a87c68c2ead1349
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Epithelial\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	MYO9A PTPN13 HPN PLEKHA7 ARHGEF28 PARD3B ARHGAP6 SLC12A1	2.61e-06	196	196	8	eea66711a16134f86e6c533a5a837ff2e0d7ca7f
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	MYO9A PPM1H PTPN13 HPN PLEKHA7 ARHGEF28 PARD3B ARHGAP6	2.61e-06	196	196	8	6ce74aa3f0ce3ca284b67e5a4660ffd2cc9611e0
ToppCell	systemic_lupus_erythematosus-treated-Lymphocytic-lymphocyte-female\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	CENPF MCM5 KIF14 SGO2 TICRR TEDC2 PKMYT1 ESPL1	2.71e-06	197	196	8	21861d8b389fafbdb7c3499684c9b6deee3dbd5e
ToppCell	systemic_lupus_erythematosus-treated-Lymphocytic-lymphocyte\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	CENPF MCM5 KIF14 SGO2 TICRR TEDC2 PKMYT1 ESPL1	2.71e-06	197	196	8	ffb004c37cdd26cb7cdcd80f769a2eded65416dc
ToppCell	systemic_lupus_erythematosus-treated-Lymphocytic\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	CENPF MCM5 KIF14 SGO2 TICRR TEDC2 PKMYT1 ESPL1	2.71e-06	197	196	8	4b13335a43b9d6abc8e542e72440da7feb82fbe6
ToppCell	(3)_DC_Monocyte_Dividing\|World / Lung cell shreds - cell class (v4) and cell subclass (v4)	CENPF MCM5 KIF14 SGO2 TICRR TEDC2 PKMYT1 ESPL1	2.82e-06	198	196	8	e2b89f6d7c0007ccab62495cd543fe0e5513a9a4
ToppCell	normal_Lymph_Node-T/NK_cells-Undetermined\|T/NK_cells / Location, Cell class and cell subclass	CENPF MCM5 KIF14 SGO2 TICRR TEDC2 PKMYT1 ESPL1	2.82e-06	198	196	8	47d572b9db2843aeb2079f33a852babf67270be4
ToppCell	distal-Hematologic-Proliferating_Macrophage-1\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	CENPF KIF14 GPSM2 SGO2 TICRR TEDC2 PKMYT1 ESPL1	2.82e-06	198	196	8	2b0716e900bce54ad1825d6dcdaf4ebf31f355c4
ToppCell	cycling_basal_cell\|World / shred by cell class for turbinate	CENPF MCM5 KIF14 SGO2 TICRR TEDC2 PKMYT1 ESPL1	2.82e-06	198	196	8	e86c1224f5b0890a50a25257628e90c790aae7cd
ToppCell	medial-Hematologic-Proliferating_Macrophage\|medial / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	CENPF KIF14 GPSM2 SGO2 TICRR POLE PKMYT1 ESPL1	2.82e-06	198	196	8	da6963184c32761c896a9b91a5321ad84b583736
ToppCell	medial-2-Hematologic-Proliferating_Macrophage\|2 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	CENPF KIF14 GPSM2 SGO2 TICRR POLE PKMYT1 ESPL1	2.82e-06	198	196	8	64a2bcf5a9ba66a4fe08fbde33f1886c136cde8f
ToppCell	Tracheal-NucSeq-Stromal-Myofibroblastic\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	HDAC9 SPEG DES KCNA5 SULF1 C11orf96 ARHGAP6 TMOD1	2.82e-06	198	196	8	c12e7511628db819a52959bb68580e27c00c2e41
ToppCell	medial-Hematologic-Proliferating_Macrophage-2\|medial / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	CENPF KIF14 GPSM2 SGO2 TICRR POLE PKMYT1 ESPL1	2.82e-06	198	196	8	fcc14ac3eb5088b9d6cd6af5a34dee5b81c0ece8
ToppCell	mild_COVID-19-T/NK_proliferative\|World / disease group, cell group and cell class (v2)	CENPF MCM5 KIF14 SGO2 TICRR TEDC2 PKMYT1 ESPL1	2.92e-06	199	196	8	d44cc74d7171d96add61dae821daf774b17d4c69
ToppCell	Healthy_donor-T/NK_proliferative\|World / disease group, cell group and cell class (v2)	CENPF MCM5 KIF14 SGO2 TICRR TEDC2 PKMYT1 ESPL1	2.92e-06	199	196	8	1311dfd74b991f48b047a439f04f9bf7dfaa0e7a
ToppCell	Control_saline-Epithelial_alveolar-AT_1-Differentiating_AT2\|Control_saline / Treatment groups by lineage, cell group, cell type	MCM5 EPS8L1 DLGAP3 PTPN13 FGF9 PLEKHA7 TNS4 USP54	3.03e-06	200	196	8	eac33be484dc443794e66e473f03e98406c2983e
ToppCell	Sigmoid-T_cell-cycling_gd_T\|T_cell / Region, Cell class and subclass	HDAC9 CENPF KIF14 GPSM2 RPH3AL C2CD2 MICAL2 ESPL1	3.03e-06	200	196	8	4e489ecf472857357d45e9f6c7a812aa48b72ebf
ToppCell	healthy_donor-Lymphocytic-Proliferative_Lymphocyte\|healthy_donor / Disease condition, Lineage, Cell class and subclass	CENPF MCM5 KIF14 SGO2 TICRR TEDC2 PKMYT1 ESPL1	3.03e-06	200	196	8	e4eb915c29909cf8535a3603c68976545c05e54b
ToppCell	Bronchial-NucSeq-Stromal-Myofibroblastic\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	SPEG DES HMCN2 KCNA5 SULF1 C11orf96 ARHGAP6 TMOD1	3.03e-06	200	196	8	a66449b22b39dd6987fc2c3ed160d24564234ced
ToppCell	healthy_donor-Lymphocytic-Proliferative_Lymphocyte-\|healthy_donor / Disease condition, Lineage, Cell class and subclass	CENPF MCM5 KIF14 SGO2 TICRR TEDC2 PKMYT1 ESPL1	3.03e-06	200	196	8	415e7556b5ac45688e2c6c30a52bd40e0eb27c7d
ToppCell	Children_(3_yrs)-Mesenchymal-airway_smooth_muscle_cell-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	SPEG DES HMCN2 TICRR ARHGAP6 TMOD1 NKAPL	5.77e-06	155	196	7	cd7d95cbcad248670e531d80bb83c55e36ebc573
ToppCell	mild_COVID-19_(asymptomatic)-pDC\|mild_COVID-19_(asymptomatic) / disease group, cell group and cell class (v2)	MAP1A KCNA5 MPP3 ZNF789 ABCB9 SAMD11 SLC6A20	9.78e-06	168	196	7	968405ea56f7d001ef83ff9274610923c3b2d55d
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Immune-Myeloid-Macrophage_Dendritic-Cycling_Mononuclear_Phagocyte\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	HDAC9 CENPF TRPM2 SIGLEC5 TICRR KCNK13 PKMYT1	1.14e-05	172	196	7	ef33b5e0515c6d29fb6d9a673011c1b68ef264f3
ToppCell	10x5'-bone_marrow-Lymphocytic_NK-Cycling_NK\|bone_marrow / Manually curated celltypes from each tissue	CENPF KIF14 GPSM2 SGO2 PKMYT1 SLC6A20 ESPL1	1.18e-05	173	196	7	8a9dd85f718564c07cf3120ad648daeb60c94fc5
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast-kidney_interstitial_fibroblast_5\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	TOPAZ1 SPEG TRPM2 KCNA5 VCL MPP3 COL6A3	1.18e-05	173	196	7	ab6d3507301038f944ad59ccd848b5e6eeb76d04
ToppCell	PND28-Endothelial-Endothelial_blood-vessel-Microvascular_EC-EPC\|PND28 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	CENPF STK11IP PLEKHG5 KIF14 SGO2 PKMYT1 ESPL1	1.23e-05	174	196	7	c6087fd0e036ec7f40f0f8f17d1f6ce13ddb5235
ToppCell	PND03-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_airway-SCMF-SCMF_G2M\|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	CENPF DES KIF14 SGO2 PPFIA3 PKMYT1 ESPL1	1.23e-05	174	196	7	7b2f35add804981c7d588a996bdbca6ec11a1ca5
ToppCell	10x5'-GI_small-bowel-Lymphocytic_T_CD4/8-lo-Cycling_T\|GI_small-bowel / Manually curated celltypes from each tissue	CENPF KIF14 SGO2 TICRR TEDC2 PKMYT1 ESPL1	1.23e-05	174	196	7	e4c8da80eca07e4396f57dad212f76c2eca4c1bd
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	CENPF KIF14 GPSM2 SGO2 TICRR POLE PKMYT1	1.23e-05	174	196	7	84da9faff088d05233183b425385beb054c92d1b
ToppCell	PND28-Endothelial-Endothelial_blood-vessel-Microvascular_EC-EPC-EPC_G2M\|PND28 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	CENPF STK11IP PLEKHG5 KIF14 SGO2 PKMYT1 ESPL1	1.23e-05	174	196	7	72df66319f6efbd88ecf439013d97409fbf3cb52
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling-Cycling_Proximal_Tubule_Epithelial_Cell_G2M\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	CENPF KIF14 GPSM2 SGO2 TICRR PKMYT1 ESPL1	1.23e-05	174	196	7	dbb4e1a6c3319ce40f81bfd2d1745a88a2cc412e
ToppCell	droplet-Lung-18m-Hematologic-myeloid-myeloid_dendritic_cell-proliferating_dendritic\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	MCM5 SGO2 TICRR POLE BARX2 PPFIA3 PKMYT1	1.27e-05	175	196	7	a6913f992a1ea20b43e5adeca3ede3a6fda820ad
ToppCell	facs-Marrow-KLS-18m-Lymphocytic-early_pro_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	N4BP3 ADRB1 SHE DNAH8 SHROOM2 HMCN1 FAM107A	1.32e-05	176	196	7	7292e014b8f697f0c2e9f47c48333de95cb44a69
ToppCell	facs-Marrow-KLS-18m-Lymphocytic-early_pro-B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	N4BP3 ADRB1 SHE DNAH8 SHROOM2 HMCN1 FAM107A	1.32e-05	176	196	7	88ca2f83d8301633232735f39b0683efe49d0b86
ToppCell	facs-Skin-Anagen-24m-Epithelial-keratinocyte_stem_cell\|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CENPF ANKDD1B KIF14 SGO2 DNAH8 TICRR ESPL1	1.37e-05	177	196	7	e9d7682517fb30fd2ad535d59779d718a7024c13
ToppCell	facs-Skin-Anagen-24m-Epithelial-actively_dividing_stem_cell\|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CENPF ANKDD1B KIF14 SGO2 DNAH8 TICRR ESPL1	1.37e-05	177	196	7	8a0f0fbb06cdacb99a3fdba0da3e0494b891db4f
ToppCell	3'_v3-Lung-Myeloid_Monocytic-Cycling_mono\|Lung / Manually curated celltypes from each tissue	CENPF MCM5 GPRIN1 VCL POLE TNS4 USP54	1.42e-05	178	196	7	67aa17b17da3121c199af45e747c23e2626a9bb2
ToppCell	PBMC_fresh-frozen-Severe-critical_convalescent_d42-56-Lymphocytic-Lymphocytic_ILC-NK_cell-NK_c03-MKI67\|Severe-critical_convalescent_d42-56 / Compartment, severity and other cell annotations on 10x 3' data (130k)	CENPF KIF14 SGO2 TICRR TEDC2 PKMYT1 CDH24	1.42e-05	178	196	7	dbde3305e0c6a81593fe614e3f2e746b32cc16a7
ToppCell	10x5'-blood-Lymphocytic_NK-Cycling_NK\|blood / Manually curated celltypes from each tissue	CENPF MCM5 C11orf96 KIF14 SGO2 TEDC2 PKMYT1	1.48e-05	179	196	7	c93711273055a999335ba8d0f6500e4549f46cec
ToppCell	LPS-antiTNF-Epithelial_alveolar-AT_2\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PTPN13 HPN MPP3 ARHGEF28 MICAL2 TNS4 USP54	1.53e-05	180	196	7	b798a3fa2dd15b68aa4267f665559527043dcc07
ToppCell	droplet-Kidney-nan-18m-Epithelial-Stroma____kidney_mesangial_cell\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MAP1A SPEG DES KCNA5 C11orf96 COL6A3 KHDRBS2	1.53e-05	180	196	7	b6f44fdedc33b7d93b0074e8e9c8cc32009d4c4d
ToppCell	LPS-antiTNF-Epithelial_alveolar-AT_2-AT2\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PTPN13 HPN MPP3 ARHGEF28 MICAL2 TNS4 USP54	1.64e-05	182	196	7	1e2149b222a3e9f64841aed45288a6f29394e7b0
ToppCell	droplet-Lung-LUNG-30m-Lymphocytic-Proliferating_NK\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CENPF MCM5 TXK SGO2 TICRR POLE TMEM121	1.64e-05	182	196	7	0370b395ceb9d4d66f80cf60dd8c28ac60af5c7b
ToppCell	droplet-Lung-18m-Hematologic-myeloid-classical_monocyte_proliferating\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	CENPF MCM5 KIF14 SGO2 POLE BARX2 ESPL1	1.70e-05	183	196	7	6c1d7ce60e67bf1df364a4e177c351e7313eb41f
ToppCell	droplet-Lung-18m-Hematologic-lymphocytic-Proliferating_T_cell-proliferating_T\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	CENPF MCM5 KIF14 SGO2 TICRR POLE TMEM121	1.76e-05	184	196	7	1edefa2a049d7e22d0bdb1ea3d7ef1c8d6ae0fe3
ToppCell	droplet-Lung-18m-Hematologic-lymphocytic-Proliferating_T_cell\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	CENPF MCM5 KIF14 SGO2 TICRR POLE TMEM121	1.76e-05	184	196	7	8578c50eaa8ce1cefc0228185c66c8e25f4bfc32
ToppCell	LPS-antiTNF-Epithelial_alveolar-AT_2-Differentiating_AT2\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PTPN13 HPN MPP3 ARHGEF28 MICAL2 TNS4 USP54	1.76e-05	184	196	7	ab2f06906fc7a9931dfa0864ef506832b07fb93e
ToppCell	Control-T_cells-Cycling_NK/T_cells\|Control / group, cell type (main and fine annotations)	CENPF KIF14 SGO2 TICRR KIF7 PKMYT1 ESPL1	1.83e-05	185	196	7	9766216b41ee62bbac4caa25cb98ec5627a24075
ToppCell	wk_15-18-Epithelial-Distal_epithelial_progenitor-epi-tip_intermediate\|wk_15-18 / Celltypes from embryonic and fetal-stage human lung	TSPOAP1 HLCS SOCS7 HPN PLEKHA7 POLE FBXL19	1.83e-05	185	196	7	636505a3d96f75d951ab42bcf8af6ae07abc732d
ToppCell	Dividing_Macrophages-Myositis-ILD_01\|World / lung cells shred on cell class, cell subclass, sample id	CENPF KIF14 GPSM2 SGO2 TICRR PKMYT1 ESPL1	1.89e-05	186	196	7	0067eb78d4c7e32b9563550d9fcaf13445ee6a48
ToppCell	TCGA-Pancreas-Primary_Tumor-Pancreatic_Adenocarcinoma-Ductal_Adenocarcinoma-1\|TCGA-Pancreas / Sample_Type by Project: Shred V9	USP34 STAG1 LUZP1 PARD3B USP37 ARHGAP6 HMCN1	1.89e-05	186	196	7	03db813598b67b1e08f759758a1c2023396921fa
ToppCell	LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_2-Differentiating_AT2\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PTPN13 HPN PLEKHA7 MPP3 ARHGEF28 MICAL2 USP54	1.89e-05	186	196	7	e83718fabb057100835d3357df407f283d23fe16
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Cycling_Myofibroblast-\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	CENPF SULF1 KIF14 SGO2 TICRR COL6A3 TEDC2	1.96e-05	187	196	7	e41e39fd3791acf8ae5376cc5061e196d96868ae
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Cycling_Myofibroblast\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	CENPF SULF1 KIF14 SGO2 TICRR COL6A3 TEDC2	1.96e-05	187	196	7	cefa211ef224e803ea9467882e2ca74d0b1492f1
ToppCell	3'-Broncho-tracheal-Immune_Lymphocytic-Lymphocytic_T/NK-natural_killer_cell-NK_cells-NK_cells_L.1.3.2.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CENPF KIF14 SGO2 TICRR TEDC2 PKMYT1 ESPL1	2.02e-05	188	196	7	319fbeca200ab998daf49fcaee0bfdb57bf7ee4b
ToppCell	renal_medulla_nuclei\|World / Celltypes from Cells and Nuclei per compartment and clinical group	STAG1 MYO9A PTPN13 ADAMTS15 PLEKHA7 PARD3B SLC12A1	2.09e-05	189	196	7	830d9cd0dd706bce22eb2416f07b2c31c870a05a
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast-\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	DES HMCN2 SULF1 C11orf96 COL6A3 MICAL2 TMOD1	2.17e-05	190	196	7	2e88e366d377d74deb53a4ea870973ce5c6532e8
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	DES HMCN2 SULF1 C11orf96 COL6A3 MICAL2 TMOD1	2.17e-05	190	196	7	0028f886c789ba238c031eae5d96acaed4af8c25
ToppCell	droplet-Kidney-nan-21m-Epithelial-Stroma____kidney_mesangial_cell\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MAP1A SPEG TRPC6 DES KCNA5 C11orf96 KIF7	2.17e-05	190	196	7	e04f47705851563515b6a66a2634cf7a574f7bda
ToppCell	droplet-Spleen-nan-18m-Lymphocytic-immature_NKT_cell\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CENPF MCM5 KIF14 GPSM2 SGO2 DNAH8 ESPL1	2.17e-05	190	196	7	b99271d139c8d01e20feb95d99f79c9b2756b4cb
ToppCell	Globus_pallidus-Neuronal\|Globus_pallidus / BrainAtlas - Mouse McCarroll V32	PSD TSPOAP1 GPRIN1 FGF9 PDZD4 MPP3 CNTNAP2	2.17e-05	190	196	7	416de85d8841dac883faa6f5339b2fb461a09e82
ToppCell	(02)_Cycling_Basal_(regeneration)\|World / shred by cell type and Timepoint	CENPF MCM5 GPSM2 SGO2 POLE SHMT2 ESPL1	2.17e-05	190	196	7	53f017a11ca5ebe9025558e12cedc409cab2e5aa
ToppCell	LPS-antiTNF-Epithelial_alveolar-Mes-Like-Differentiating_AT1\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MAP1A SPEG HMCN2 PIGO ZFHX4 FAM107A	2.21e-05	128	196	6	2cf0384240a4a663869cf6b27d954236f6214a9a
ToppCell	3'_v3-GI_small-bowel-Lymphocytic_T_CD4/8-lo-Cycling_T\|GI_small-bowel / Manually curated celltypes from each tissue	CENPF KIF14 SGO2 TICRR TEDC2 PKMYT1 ESPL1	2.24e-05	191	196	7	e642fa7395c05fb53324c9d46bbc52f89fc9673f
ToppCell	systemic_lupus_erythematosus-managed-Lymphocytic-lymphocyte-male\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	CENPF MCM5 KIF14 TICRR TEDC2 PKMYT1 ESPL1	2.24e-05	191	196	7	56b45259dfc38bd5ea43b0e3adf47e7e2c043a5d
ToppCell	3'-Distal_airway-Immune_Myeloid-Myeloid_macrophage-alveolar_macrophage-Alveolar_macrophage_proliferating-Alveolar_macrophage_proliferating_L.1.0.7.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CENPF MCM5 KIF14 SGO2 TICRR PKMYT1 ESPL1	2.24e-05	191	196	7	b85a0978dc1e8af4f49423f56dcfd52efce09ed1
ToppCell	saliva-Severe-critical_progression_d12-22_no-steroids-Epithelial-Epithelial,_Airway-secretory_cell-Epi-Secretory\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	EPS8L1 PTPN13 ANKDD1B MPP3 SHROOM2 STS AHNAK2	2.32e-05	192	196	7	8899d81306770adda893b5e146df1253971754c5
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell-\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	SPEG DES KCNA5 C11orf96 MICAL2 TMOD1 ZFHX3	2.32e-05	192	196	7	bfab13793e54de2550ee171397f7ece0625cdb4a
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	SPEG DES KCNA5 C11orf96 MICAL2 TMOD1 ZFHX3	2.32e-05	192	196	7	b54b0d5b88139905521c8d5d58332e89c08d589c
ToppCell	droplet-Kidney-nan-3m-Epithelial-kidney_mesangial_cell\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MAP1A SPEG TRPC6 DES KCNA5 C11orf96 ZFHX3	2.32e-05	192	196	7	3617d2bc7e33d981f3ec349e9962d8d4bd822fbd
ToppCell	PND10-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular-VSMC-VSMC_mature\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MAP1A SPEG DES KCNA5 ADAMTS15 PLXNA1 ZFHX3	2.32e-05	192	196	7	26d9207e72bbef5e0046de511e2c9ff752b726f3
ToppCell	saliva-Severe-critical_progression_d12-22_no-steroids-Epithelial-Epithelial,_Airway-secretory_cell\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	EPS8L1 PTPN13 ANKDD1B MPP3 SHROOM2 STS AHNAK2	2.32e-05	192	196	7	5fda9a465c9f77c7fa1a3ea07a2b0374bbc23b2a
ToppCell	Severe_COVID-19-Myeloid-proliferating_Myeloid_cells\|Severe_COVID-19 / Disease group,lineage and cell class （2021.01.30）	CENPF CHDH KIF14 GPSM2 SGO2 TEDC2 PKMYT1	2.40e-05	193	196	7	0d85025690c9cd545cba30abc38acbdd6a39b153
ToppCell	Control-Lymphoid-Proliferating_CD4_T_cells\|Control / Condition, Lineage and Cell class	CENPF KIF14 GPSM2 SGO2 TICRR PKMYT1 ESPL1	2.40e-05	193	196	7	33d409d6ed1c606337248587ad997ac5f67f081d
ToppCell	PND10-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular-VSMC\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MAP1A SPEG DES KCNA5 ADAMTS15 PLXNA1 ZFHX3	2.40e-05	193	196	7	7fc3ab7261c88c1df71744bf5b17e8e46c4300e0
ToppCell	PBMC-Control-Lymphocyte-T/NK-Other_T-T/NK_proliferative\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CENPF MCM5 KIF14 TICRR TEDC2 PKMYT1 ESPL1	2.48e-05	194	196	7	f39a471293ecc5c5967b00e772b8f48ebc9affbe
ToppCell	3'_v3-Lung-Myeloid_Mac-Cycling_Myeloid-Mac\|Lung / Manually curated celltypes from each tissue	CENPF MCM5 KIF14 SGO2 TEDC2 PKMYT1 ESPL1	2.48e-05	194	196	7	a8ae49157ca3f9e8b3f1750a995aee012dc859b6
ToppCell	BAL-Severe-Myeloid-Myeloid\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CENPF CHDH KIF14 GPSM2 SGO2 TEDC2 PKMYT1	2.48e-05	194	196	7	2360b5f995b360419de41612368cab9fb61781a1
ToppCell	BAL-Severe-Myeloid-Myeloid-proliferating_Myeloid_cells\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	CENPF CHDH KIF14 GPSM2 SGO2 TEDC2 PKMYT1	2.48e-05	194	196	7	903ae11708b0cb24538c6982abd57fe6fa95b8d3
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	MYO9A PTPN13 HPN PLEKHA7 ARHGEF28 ARHGAP6 SLC12A1	2.48e-05	194	196	7	93c68c31e39fa44c1d05d7d4997f4f086da4e738
ToppCell	PBMC-Control-Lymphocyte-T/NK-Other_T-T/NK_proliferative-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	CENPF MCM5 KIF14 TICRR TEDC2 PKMYT1 ESPL1	2.48e-05	194	196	7	a75ecd0b0a928d4646602f7d16a645f6b3df3af5
ToppCell	kidney_cells-Renal_AKI_(acute_kidney_injury)-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling-Cycling_Proximal_Tubule_Epithelial_Cell_S-high\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	CENPF MCM5 KIF14 TICRR POLE TEDC2 PKMYT1	2.48e-05	194	196	7	4c1d13d8cb6fb424655c67755ee6dbaf59d6b418
ToppCell	PBMC-Control-Lymphocyte-T/NK-Other_T-T/NK_proliferative-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CENPF MCM5 KIF14 TICRR TEDC2 PKMYT1 ESPL1	2.48e-05	194	196	7	17744fd6645cf5a447a01a83f07e8d305c2bcd9c
Drug	Methapyrilene hydrochloride [135-23-9]; Up 200; 13.4uM; MCF7; HT_HG-U133A	CPLANE2 HLCS SPTBN5 DES ADRB1 FGF9 PIGO DVL3 ABCB9 CNTNAP2 TMOD1 MAST3 KIF1C	1.26e-08	199	189	13	3205_UP
Drug	prochlorperazine dimaleate salt; Down 200; 10uM; PC3; HT_HG-U133A	CENPF SPEG SLC41A3 FBXO42 PRRC2A PLXNA1 MPP3 TEDC2 ASAP3 SHROOM2 CNTNAP2 MAST3	1.01e-07	197	189	12	1215_DN
Drug	Nafronyl oxalate [3200-06-4]; Down 200; 8.4uM; PC3; HT_HG-U133A	CENPF MYO9A MCL1 TRMT12 SUPT20H ASAP3 PPFIA3 SHROOM2 TMEM121 CNTNAP2 MAST3	8.68e-07	198	189	11	6687_DN
Drug	Monobenzone [103-16-2]; Down 200; 20uM; MCF7; HT_HG-U133A	USP34 CENPF SPEG HLCS MCL1 KIF14 GPSM2 TNS3 HBEGF GPRIN2	3.70e-06	186	189	10	3391_DN
Drug	Methylhydantoin-5-(D) [55147-68-7]; Up 200; 35uM; MCF7; HT_HG-U133A	MAP1A TRPM2 SOCS7 SPTBN5 DES DLGAP4 BAZ2A CNTNAP2 KIF1C HR	6.74e-06	199	189	10	3333_UP
Drug	haloperidol; Down 200; 10uM; HL60; HT_HG-U133A	MAP1A TRIO DES KCNA5 PIGO MTHFSD KHDRBS2 STS KIF1C	3.83e-05	195	189	9	2663_DN
Drug	Lobelanidine hydrochloride [6112-86-3]; Up 200; 10.6uM; MCF7; HT_HG-U133A	LARP6 N4BP3 DLGAP4 THOC5 TMEM121 ABCB9 FAM107A CNTNAP2 HR	3.83e-05	195	189	9	2897_UP
Drug	Fluorometholone [426-13-1]; Up 200; 10.6uM; MCF7; HT_HG-U133A	TRIO CENPF HLCS DES KCNA5 ASAP3 ABCB9 BAZ2A CNTNAP2	3.83e-05	195	189	9	6071_UP
Drug	Testosterone propionate [57-85-2]; Down 200; 11.6uM; PC3; HT_HG-U133A	PIGO KHDRBS2 CHD7 OCA2 ARHGAP6 ABCB9 SLC6A20 CNTNAP2 MAST3	3.83e-05	195	189	9	4676_DN
Drug	Naloxone hydrochloride [357-08-4]; Up 200; 11uM; MCF7; HT_HG-U133A	SPEG TRPM2 INSR HLCS DES ASAP3 BARX2 ARHGAP6 CNTNAP2	3.99e-05	196	189	9	5606_UP
Drug	Acacetin [480-44-4]; Up 200; 14uM; MCF7; HT_HG-U133A	SPEG PRRC2A ARHGEF28 ASAP3 ABCB9 CUZD1 GPRIN2 KIF1C HR	3.99e-05	196	189	9	3849_UP
Drug	Denatonium benzoate [3734-33-6]; Down 200; 9uM; PC3; HT_HG-U133A	HDAC9 SPEG MRM1 EPS8L1 CHD7 STS CNTNAP2 MAST3 KIF1C	3.99e-05	196	189	9	5061_DN
Drug	Famotidine [76824-35-6]; Down 200; 11.8uM; MCF7; HT_HG-U133A	USP34 MYO9A HLCS N4BP3 DVL3 ZNF34 HABP4 STS GPRIN2	3.99e-05	196	189	9	5011_DN
Drug	Ethambutol dihydrochloride [1070-11-7]; Up 200; 14.4uM; MCF7; HT_HG-U133A	SPEG SOCS7 DLGAP4 FAM107A SLC6A20 CNTNAP2 GPRIN2 AHNAK2 KIF1C	4.15e-05	197	189	9	4120_UP
Drug	Orphenadrine hydrochloride [341-69-5]; Down 200; 13uM; PC3; HT_HG-U133A	TRIO PIGO ARHGAP6 ABCB9 BAZ2A CNTNAP2 TNS4 GPRIN2 HR	4.15e-05	197	189	9	3801_DN
Drug	Flunarizine dihydrochloride [30484-77-6]; Up 200; 8.4uM; MCF7; HT_HG-U133A	TRPM2 N4BP3 DES HPN OTUD3 MTHFSD INHBE DVL3 ZFHX4	4.15e-05	197	189	9	7412_UP
Drug	Lisuride (S)(-) [18016-80-3]; Down 200; 11.8uM; MCF7; HT_HG-U133A	TRPM2 LUZP1 HPN HBEGF DLGAP4 DVL3 PPFIA3 ZNF34 MAST3	4.15e-05	197	189	9	1545_DN
Drug	Pentolinium bitartrate [52-62-0]; Up 200; 7.4uM; MCF7; HT_HG-U133A	TSPOAP1 TXK SPTBN5 ASAP3 STS ABCB9 AHNAK2 KIF1C HR	4.15e-05	197	189	9	2305_UP
Drug	Hexestrol [84-16-2]; Down 200; 14.8uM; MCF7; HT_HG-U133A	CENPF FBXO42 PLXNA1 UBE3B STS ABCB9 MICAL2 GPRIN2 KIF1C	4.15e-05	197	189	9	6077_DN
Drug	Noscapine [128-62-1]; Down 200; 9.6uM; PC3; HT_HG-U133A	MYO9A SPEG DES SLC41A3 MPP3 ARHGEF28 TEDC2 MTMR14 ZFHX3	4.15e-05	197	189	9	5851_DN
Drug	troglitazone; Up 200; 10uM; MCF7; HT_HG-U133A	CPLANE2 TRPM2 KHDRBS2 DVL3 OCA2 THOC5 ZFHX4 TMOD1 ZFHX3	4.15e-05	197	189	9	6991_UP
Drug	Loxapine succinate [27833-64-3]; Up 200; 9uM; MCF7; HT_HG-U133A	USP34 EPS8L1 GGCX FGF9 MPP3 INHBE ZFHX4 ABCB9 HR	4.31e-05	198	189	9	1516_UP
Drug	Tracazolate hydrochloride [41094-88-6]; Up 200; 11.8uM; MCF7; HT_HG-U133A	INHBE ASAP3 DVL3 ZFHX4 MICAL2 CUZD1 TMOD1 MAST3 AHNAK2	4.31e-05	198	189	9	4964_UP
Drug	Imipenem [74431-23-5]; Up 200; 13.4uM; PC3; HT_HG-U133A	TRIO TRPM2 PIGO THOC5 STS CELSR2 ABCB9 CNTNAP2 GPRIN2	4.31e-05	198	189	9	7294_UP
Drug	Gabapentin [60142-96-3]; Up 200; 23.4uM; PC3; HT_HG-U133A	TSPOAP1 MRM1 INSR MTHFSD PARP8 ASAP3 TMEM121 STS HR	4.31e-05	198	189	9	5875_UP
Drug	haloperidol; Down 200; 10uM; PC3; HT_HG-U133A	SPEG HLCS RAD51D POLG TMEM121 ZNF34 CELSR2 BAZ2A CNTNAP2	4.31e-05	198	189	9	1244_DN
Drug	Cotinine (-) [486-56-6]; Down 200; 22.6uM; MCF7; HT_HG-U133A	EPS8L1 CLIP1 MPP3 ZNF34 ZFHX4 ABCB9 CUZD1 TMOD1 MAST3	4.31e-05	198	189	9	5246_DN
Drug	Fluocinonide [356-12-7]; Up 200; 8uM; MCF7; HT_HG-U133A	TSPOAP1 MRM1 HLCS ASAP3 DVL3 PPFIA3 MICAL2 CNTNAP2 HR	4.31e-05	198	189	9	3414_UP
Drug	estradiol, USP; Down 200; 0.01uM; HL60; HG-U133A	TRIO MYO9A INSR PLXNA1 SPEF1 POLG ASAP3 BAZ2A MAST3	4.31e-05	198	189	9	387_DN
Drug	Althiazide [5588-16-9]; Down 200; 10.4uM; MCF7; HT_HG-U133A	INSR HLCS EPS8L1 PIGO RAD51D RPH3AL DLGAP4 STS MAST3	4.31e-05	198	189	9	6089_DN
Drug	Methoxamine hydrochloride [61-16-5]; Up 200; 16.2uM; MCF7; HT_HG-U133A	TRIO N4BP3 SOCS7 DES PIGO MPP3 INHBE DVL3 ZFHX4	4.31e-05	198	189	9	2848_UP
Drug	Tamoxifen citrate [54965-24-1]; Up 200; 7uM; PC3; HT_HG-U133A	HDAC9 HLCS EPS8L1 SUPT20H POLG ZNF34 HABP4 ABCB9 TNS4	4.49e-05	199	189	9	2050_UP
Drug	Naftopidil dihydrochloride [57149-08-3]; Down 200; 8.6uM; MCF7; HT_HG-U133A	HLCS SULF1 PLXNA1 SUPT20H TMEM121 HABP4 ABCB9 BAZ2A LRRFIP1	4.49e-05	199	189	9	7331_DN
Drug	cyclosporine A; Down 200; 1uM; MCF7; HG-U133A	LUZP1 FBXO42 COL6A3 ARHGEF28 DLGAP4 TMEM121 BAZ2A MAST3 KIF1C	4.66e-05	200	189	9	261_DN
Drug	3-nitropropionic acid; Down 200; 10uM; PC3; HT_HG-U133A	HDAC9 MRM1 EPS8L1 PLXNA1 SUPT20H POLG ASAP3 HABP4 CNTNAP2	4.66e-05	200	189	9	6407_DN
Drug	irinotecan HCl; Down 200; 100uM; MCF7; HT_HG-U133A	STAG1 TRIO CENPF PPM1H KIF14 TNS3 CHD7 SHROOM2	1.06e-04	174	189	8	7530_DN
Drug	2,4,4'-trichlorobiphenyl	CCDC8 PSD CENPF TOPAZ1 CDH23 MCM5 SHE DNAH8 TNS3 PHLDB3 TICRR COL6A3 INHBE TRPC7 SUPT20H POLE DVL3 BARX2 ACTR3B PPFIA3 CELSR2 ZFHX4 MTMR14 MICAL2 CNTNAP2 ESPL1	1.12e-04	1411	189	26	ctd:C081766
Drug	Dipivefrin hydrochloride [64019-93-8]; Up 200; 10.4uM; HL60; HG-U133A	TRPM2 MCL1 LUZP1 FBXO42 GPSM2 WIPF2 MICAL2 LRRFIP1	1.35e-04	180	189	8	1752_UP
Drug	Lycorine hydrochloride [2188-68-3]; Down 200; 12.4uM; PC3; HT_HG-U133A	LARP6 PPM1H TXK COL6A3 TEDC2 STS ABCB9 GPRIN2	1.45e-04	182	189	8	3808_DN
Drug	2,4,5,2',5'-pentachlorobiphenyl	CCDC8 PSD CENPF TOPAZ1 CDH23 MCM5 SHE DNAH8 TNS3 PHLDB3 TICRR COL6A3 INHBE TRPC7 SUPT20H POLE DVL3 BARX2 ACTR3B PPFIA3 CELSR2 ZFHX4 MTMR14 MICAL2 CNTNAP2 ESPL1	1.57e-04	1441	189	26	ctd:C009828
Drug	Methotrexate [59-05-2]; Down 200; 8.8uM; HL60; HG-U133A	STAG1 CENPF TRPM2 ABT1 KIF14 WIPF2 MTMR14 LRRFIP1	1.88e-04	189	189	8	2041_DN
Drug	Digoxin [20830-75-5]; Down 200; 5.2uM; PC3; HT_HG-U133A	MAP1A HLCS TRMT12 SUPT20H CHD7 SHROOM2 ARHGAP6 LRRFIP1	2.02e-04	191	189	8	6724_DN
Drug	Cimetidine [51481-61-9]; Down 200; 15.8uM; MCF7; HT_HG-U133A	ZBTB6 TRPM2 HLCS MPP3 OCA2 PPFIA3 BAZ2A AHNAK2	2.10e-04	192	189	8	4144_DN
Drug	Resveratrol [501-36-0]; Down 200; 17.6uM; MCF7; HT_HG-U133A	TRIO CENPF CLIP1 SULF1 KIF14 GPSM2 CUZD1 ESPL1	2.10e-04	192	189	8	2865_DN
Drug	cis-4,7,10,13,16,19-Docosahexaenoic acid ethyl ester; Up 200; 100uM; MCF7; HT_HG-U133A_EA	USP34 MAP1A TRIO EPS8L1 PIGO INHBE DLGAP4 KHDRBS2	2.17e-04	193	189	8	881_UP
Drug	Fenoterol hydrobromide [1944-12-3]; Down 200; 10.4uM; PC3; HT_HG-U133A	USP34 TRIO TRPM2 CLIP1 PPM1H TNS3 ACTR3B STS	2.17e-04	193	189	8	6331_DN
Drug	trifluoperazine dihydrochloride; Down 200; 10uM; MCF7; HT_HG-U133A	HLCS DVL3 OCA2 ABCB9 BAZ2A CNTNAP2 TMOD1 AHNAK2	2.17e-04	193	189	8	5584_DN
Drug	Y-27632; Up 200; 3uM; MCF7; HT_HG-U133A_EA	HLCS SULF1 PIGO DLGAP4 DVL3 PPFIA3 ABCB9 AHNAK2	2.17e-04	193	189	8	948_UP
Drug	Progesterone [57-83-0]; Down 200; 12.8uM; PC3; HT_HG-U133A	HLCS PIGO RAD51D DLGAP4 CHD7 TMEM121 ABCB9 HR	2.17e-04	193	189	8	6646_DN
Drug	Amiodarone hydrochloride [19774-82-4]; Up 200; 5.8uM; MCF7; HT_HG-U133A	MAP1A SPEG SOCS7 SPTBN5 VCL INHBE BAZ2A SLC6A20	2.17e-04	193	189	8	3296_UP
Drug	retinoic acid; Down 200; 1uM; PC3; HT_HG-U133A	USP34 WIPF2 PLXNA1 TEDC2 ASAP3 STS CNTNAP2 GPRIN2	2.25e-04	194	189	8	1211_DN
Drug	Vincamine [1617-90-9]; Down 200; 11.2uM; PC3; HT_HG-U133A	ZBTB6 HLCS MCL1 TXK PIGO PPFIA3 STS ZFHX3	2.25e-04	194	189	8	4341_DN
Drug	Cholecalciferol [67-97-0]; Down 200; 10.4uM; PC3; HT_HG-U133A	INSR HLCS TEDC2 TMEM121 ABCB9 CNTNAP2 ZFHX3 HR	2.25e-04	194	189	8	6656_DN
Drug	Spiramycin [8025-81-8]; Up 200; 4.8uM; MCF7; HT_HG-U133A	KCNA5 VCL ARHGEF28 HBEGF KHDRBS2 ZFHX4 SLC6A20 HR	2.25e-04	194	189	8	3938_UP
Drug	0179445-0000 [211246-22-9]; Down 200; 1uM; MCF7; HT_HG-U133A	LARP6 EPS8L1 LUZP1 PIGO DLGAP4 TMEM121 CNTNAP2 CUZD1	2.25e-04	194	189	8	4758_DN
Drug	17-AAG; Up 200; 1uM; MCF7; HT_HG-U133A	USP34 ZBTB6 HLCS CLIP1 HPN DLGAP4 ASAP3 BAZ2A	2.33e-04	195	189	8	1650_UP
Drug	5-aminosalicylic acid; Up 200; 100uM; MCF7; HG-U133A	CENPF MRM1 EPS8L1 LUZP1 SLC41A3 POLG ZFHX4 HR	2.33e-04	195	189	8	124_UP
Drug	Propidium iodide [25535-16-4]; Up 200; 6uM; MCF7; HT_HG-U133A	TRIO SPEG CLIP1 DES STS ABCB9 CNTNAP2 HR	2.33e-04	195	189	8	6104_UP
Drug	Mexiletine hydrochloride [5370-01-4]; Up 200; 18.6uM; MCF7; HT_HG-U133A	USP34 TRIO MCL1 HBEGF BARX2 CNTNAP2 CUZD1 GPRIN2	2.33e-04	195	189	8	3862_UP
Drug	novobiocin sodium, USP; Down 200; 100uM; SKMEL5; HG-U133A	TRIO EPS8L1 CLIP1 DES GPSM2 PRRC2A POLG HABP4	2.33e-04	195	189	8	632_DN
Drug	Lobelanidine hydrochloride [6112-86-3]; Down 200; 10.6uM; MCF7; HT_HG-U133A	MRM1 OTUD3 RAD51D MPP3 HABP4 CUZD1 TMOD1 GPRIN2	2.41e-04	196	189	8	2897_DN
Drug	Retrorsine [480-54-6]; Up 200; 11.4uM; PC3; HT_HG-U133A	SPTBN5 INHBE KHDRBS2 HABP4 STS FAM107A SLC6A20 CNTNAP2	2.41e-04	196	189	8	6601_UP
Drug	Azapropazone [13539-59-8]; Down 200; 13.4uM; PC3; HT_HG-U133A	HLCS EPS8L1 PRRC2A DR1 SUPT20H ASAP3 ACTR3B ABCB9	2.41e-04	196	189	8	7277_DN
Drug	Diclofenac sodium [15307-79-6]; Down 200; 12.6uM; PC3; HT_HG-U133A	TRIO ABT1 EPS8L1 LUZP1 DES PKMYT1 HABP4 BAZ2A	2.41e-04	196	189	8	5861_DN
Drug	sulfasalazine; Down 200; 100uM; MCF7; HG-U133A	EPS8L1 LUZP1 SPTBN5 GPSM2 OTUD3 PPFIA3 ZFHX4 KIF1C	2.41e-04	196	189	8	204_DN
Drug	Pyrimethamine [58-14-0]; Down 200; 16uM; MCF7; HT_HG-U133A	EPS8L1 OTUD3 WIPF2 DVL3 PPFIA3 TMEM121 ABCB9 TMOD1	2.41e-04	196	189	8	4779_DN
Drug	Xylazine [7361-61-7]; Up 200; 18.2uM; PC3; HT_HG-U133A	EPS8L1 DENND1C SULF1 PIGO UBE3B BAZ2A MICAL2 TNS4	2.41e-04	196	189	8	4066_UP
Drug	CP-944629 [668990-94-1]; Up 200; 10uM; PC3; HT_HG-U133A	HDAC9 CENPF TEDC2 POLG ACTR3B BAZ2A CNTNAP2 HR	2.41e-04	196	189	8	7502_UP
Drug	Econazole nitrate [24169-02-6]; Down 200; 9uM; HL60; HT_HG-U133A	TSPOAP1 EPS8L1 OTUD3 PRRC2A PLXNA1 MPP3 MTHFSD THOC5	2.41e-04	196	189	8	2396_DN
Drug	Napelline [5008-52-6]; Up 200; 11.2uM; MCF7; HT_HG-U133A	SPEG INSR SPTBN5 DES MICAL2 TMOD1 AHNAK2 HR	2.41e-04	196	189	8	6084_UP
Drug	Flupentixol dihydrochloride cis-(Z) [2413-38-9]; Down 200; 7.8uM; PC3; HT_HG-U133A	USP34 ZBTB6 CENPF MRM1 FBXO42 MTHFSD ASAP3 CNTNAP2	2.41e-04	196	189	8	6708_DN
Drug	Sulpiride [15676-16-1]; Up 200; 11.8uM; MCF7; HT_HG-U133A	USP34 HLCS N4BP3 DES HBEGF POLG ZFHX4 AHNAK2	2.49e-04	197	189	8	1467_UP
Drug	Iocetamic acid [16034-77-8]; Up 200; 6.6uM; MCF7; HT_HG-U133A	SPEG TRPM2 HLCS MPP3 ARHGEF28 DLGAP4 CNTNAP2 AHNAK2	2.49e-04	197	189	8	3361_UP
Drug	Propofol [2078-54-8]; Up 200; 22.4uM; HL60; HT_HG-U133A	TRIO TRPC6 EPS8L1 PTPN13 ADRB1 TRPC7 FAM107A ZFHX3	2.49e-04	197	189	8	3048_UP
Drug	Sulfanilamide [63-74-1]; Down 200; 23.2uM; PC3; HT_HG-U133A	SPEG CLIP1 PIGO PLXNA1 SUPT20H SHROOM2 STS BAZ2A	2.49e-04	197	189	8	4474_DN
Drug	Altretamine [654-05-6]; Up 200; 19uM; PC3; HT_HG-U133A	MRM1 INSR SULF1 PIGO RPH3AL PARP8 CNTNAP2 MAST3	2.49e-04	197	189	8	4627_UP
Drug	Ciprofloxacin hydrochloride [93107-08-5]; Up 200; 10.8uM; HL60; HG-U133A	MAP1A INSR EPS8L1 LUZP1 SUPT4H1 C2CD2 MAST3 LRRFIP1	2.49e-04	197	189	8	2022_UP
Drug	Acetaminophen [103-90-2]; Down 200; 26.4uM; MCF7; HT_HG-U133A	SPEG HLCS N4BP3 CLIP1 SLC41A3 SULF1 HABP4 AHNAK2	2.49e-04	197	189	8	3364_DN
Drug	Yohimbine hydrochloride [65-19-0]; Up 200; 10.2uM; HL60; HG-U133A	MRM1 EPS8L1 GGCX LUZP1 BAZ2A TMOD1 GPRIN2 HR	2.49e-04	197	189	8	1763_UP
Drug	U0125; Down 200; 1uM; PC3; HG-U133A	USP34 TRPM2 EPS8L1 GGCX PLXNA1 PPFIA3 FAM107A MAST3	2.49e-04	197	189	8	663_DN
Drug	Sulfamethazine sodium salt [1981-58-4]; Up 200; 13.4uM; MCF7; HT_HG-U133A	TRPM2 INSR SOCS7 ARHGEF28 DLGAP4 STS SLC6A20 TMOD1	2.49e-04	197	189	8	3940_UP
Drug	Cefalonium [5575-21-3]; Down 200; 8.8uM; MCF7; HT_HG-U133A	HLCS EPS8L1 SULF1 WIPF2 POLG PPFIA3 ABCB9 MAST3	2.49e-04	197	189	8	7341_DN
Drug	Prazosin hydrochloride [19237-84-4]; Up 200; 9.6uM; MCF7; HT_HG-U133A	POLG PARP8 DLGAP4 PPFIA3 TMOD1 MAST3 AHNAK2 KIF1C	2.49e-04	197	189	8	6475_UP
Drug	Sulfadiazine [68-35-9]; Down 200; 16uM; PC3; HT_HG-U133A	PTPN13 PIGO PLXNA1 SUPT20H ACTR3B PPFIA3 SHROOM2 MAST3	2.49e-04	197	189	8	1810_DN
Drug	Aminohippuric acid [61-78-9]; Down 200; 20.6uM; MCF7; HT_HG-U133A	MRM1 PRRC2A KHDRBS2 ABCB9 BAZ2A MICAL2 GPRIN2 HR	2.49e-04	197	189	8	6453_DN
Drug	Estrone [53-16-7]; Down 200; 14.8uM; HL60; HT_HG-U133A	INSR FGF9 UBE3B DLGAP4 ZNF34 HABP4 TMOD1 ZFHX3	2.49e-04	197	189	8	3071_DN
Drug	Zalcitabine [7481-89-2]; Down 200; 19uM; MCF7; HT_HG-U133A	HLCS LUZP1 HPN DVL3 ACTR3B HABP4 ABCB9 BAZ2A	2.49e-04	197	189	8	7352_DN
Drug	PNU-0230031 [267429-39-0]; Up 200; 1uM; MCF7; HT_HG-U133A	TRIO CENPF DES KCNA5 KHDRBS2 PPFIA3 STS HR	2.49e-04	197	189	8	3632_UP
Drug	Amodiaquin dihydrochloride dihydrate [6398-98-7]; Down 200; 8.6uM; PC3; HT_HG-U133A	HLCS EPS8L1 RAD51D TEDC2 THOC5 ARHGAP6 ABCB9 ZFHX3	2.49e-04	197	189	8	5747_DN
Drug	PNU-0293363 [326823-19-2]; Down 200; 10uM; PC3; HT_HG-U133A	TRIO MRM1 TRPM2 GGCX SUPT20H DLGAP4 ASAP3 CELSR2	2.58e-04	198	189	8	6568_DN
Drug	Benzathine benzylpenicillin [5928-84-7]; Down 200; 4.2uM; MCF7; HT_HG-U133A	TRIO HLCS LUZP1 FBXO42 POLG TMEM121 BAZ2A LRRFIP1	2.58e-04	198	189	8	7359_DN
Drug	Reserpinic acid hydrochloride; Down 200; 9.2uM; MCF7; HT_HG-U133A	EPS8L1 PTPN13 FBXO42 WIPF2 POLG ABCB9 MAST3 LRRFIP1	2.58e-04	198	189	8	7323_DN
Drug	genistein; Down 200; 10uM; PC3; HT_HG-U133A	TRIO CENPF SPEG HLCS ARHGEF28 ASAP3 BAZ2A CNTNAP2	2.58e-04	198	189	8	1235_DN
Drug	Cefazolin sodium salt [27164-46-1]; Down 200; 8.4uM; MCF7; HT_HG-U133A	MRM1 EPS8L1 SULF1 FBXO42 PIGO RAD51D HABP4 ABCB9	2.58e-04	198	189	8	3426_DN
Drug	Norgestrel-(-)-D [797-63-7]; Up 200; 12.8uM; MCF7; HT_HG-U133A	EPS8L1 LUZP1 HBEGF UBE3B OCA2 PPFIA3 CELSR2 GPRIN2	2.58e-04	198	189	8	3406_UP
Drug	Danazol [17230-88-5]; Down 200; 11.8uM; MCF7; HT_HG-U133A	USP34 HLCS LUZP1 UBE3B ABCB9 TMOD1 ZFHX3 MAST3	2.58e-04	198	189	8	1538_DN
Drug	rotenone; Down 200; 1uM; MCF7; HT_HG-U133A	ZBTB6 MAP1A RAD51D DLGAP4 PPFIA3 HABP4 BAZ2A CUZD1	2.58e-04	198	189	8	5943_DN
Drug	Boldine [476-70-0]; Down 200; 12.2uM; PC3; HT_HG-U133A	TXK RPH3AL TEDC2 UBE3B STS CNTNAP2 CUZD1 MAST3	2.58e-04	198	189	8	4004_DN
Drug	Triamcinolone [124-94-7]; Down 200; 10.2uM; PC3; HT_HG-U133A	TRIO CENPF MCL1 FBXO42 DLGAP4 BAZ2A ZFHX3 KIF1C	2.58e-04	198	189	8	5835_DN
Drug	Corynanthine hydrochloride [66634-44-4]; Down 200; 10.2uM; MCF7; HT_HG-U133A	PIGO PLXNA1 ZNF34 HABP4 BAZ2A TMOD1 MAST3 AHNAK2	2.58e-04	198	189	8	2786_DN
Disease	testosterone measurement	STAG1 MAP1A TRPM2 INSR HPN ANKDD1B FGF9 FGF11 USP3 TNS3 TRPC7 ZNF789 DLGAP4 ZNF316 KCNK13 CHD7 C2CD2 ARHGAP6 ZFHX4 HMCN1 CNTNAP2 ZFHX3 YY1AP1	8.58e-06	1275	190	23	EFO_0004908
Disease	focal segmental glomerulosclerosis (implicated_via_orthology)	MYO9A TRPC6 HR	9.02e-06	7	190	3	DOID:1312 (implicated_via_orthology)
Disease	sialic acid-binding Ig-like lectin 14 measurement	SIGLEC5 ARHGEF28 SIGLEC14	5.54e-05	12	190	3	EFO_0008284
Disease	factor VIII measurement, coronary artery disease	HDAC9 STAG1 CFDP1 PRRC2A UBE3B CELSR2	9.40e-05	113	190	6	EFO_0001645, EFO_0004630
Disease	FEV/FEC ratio	HDAC9 USP34 SPEG CDH23 MCL1 SPTBN5 PRR12 DES SULF1 CFDP1 USP3 WIPF2 MTHFSD COL6A3 ARHGEF28 KHDRBS2 HMCN1 CNTNAP2 TMOD1 ZFHX3	1.39e-04	1228	190	20	EFO_0004713
Disease	mastiha supplement exposure measurement, interleukin-6 measurement	TRPM2 TRPC7	2.45e-04	4	190	2	EFO_0004810, EFO_0600067
Disease	Paroxysmal atrial fibrillation	USP34 DES KCNA5 USP3 DNAH10 ZFHX3	5.38e-04	156	190	6	C0235480
Disease	familial atrial fibrillation	USP34 DES KCNA5 USP3 DNAH10 ZFHX3	5.38e-04	156	190	6	C3468561
Disease	Persistent atrial fibrillation	USP34 DES KCNA5 USP3 DNAH10 ZFHX3	5.38e-04	156	190	6	C2585653
Disease	pappalysin-1 measurement	USP34 CHD7	6.08e-04	6	190	2	EFO_0802845
Disease	Atrial Fibrillation	USP34 DES KCNA5 USP3 DNAH10 ZFHX3	6.15e-04	160	190	6	C0004238
Disease	coronary artery disease, plasminogen activator inhibitor 1 measurement	HDAC9 STAG1 CFDP1 CELSR2	7.37e-04	63	190	4	EFO_0001645, EFO_0004792
Disease	brain aneurysm	HDAC9 HLCS CFDP1 PARD3B TMOD1	8.40e-04	113	190	5	EFO_0003870
Disease	Oculocutaneous albinism	OCA2 WDR45	8.48e-04	7	190	2	cv:C0078918
Disease	dehydroepiandrosterone sulphate measurement	TRPC6 FGF9 RPH3AL ZNF789	9.83e-04	68	190	4	EFO_0007001
Disease	congenital heart disease (implicated_via_orthology)	USP17L1 USP17L18 USP17L3 CHD7	1.04e-03	69	190	4	DOID:1682 (implicated_via_orthology)
Disease	tissue plasminogen activator measurement, coronary artery disease	HDAC9 STAG1 CFDP1 CELSR2	1.16e-03	71	190	4	EFO_0001645, EFO_0004791
Disease	lung cancer (is_implicated_in)	MCL1 TRPC7 POLE DVL3	1.35e-03	74	190	4	DOID:1324 (is_implicated_in)
Disease	lipid measurement, high density lipoprotein cholesterol measurement	MAP1A ADRB1 ANKDD1B MPP3 INHBE DNAH10 ASAP3 CELSR2	1.41e-03	330	190	8	EFO_0004529, EFO_0004612
Disease	lung cancer (implicated_via_orthology)	POLE XPC	1.44e-03	9	190	2	DOID:1324 (implicated_via_orthology)
Disease	Agents acting on the renin-angiotensin system use measurement	HDAC9 INSR ADRB1 CFDP1 FGF9 TICRR PKMYT1 CELSR2	1.55e-03	335	190	8	EFO_0009931
Disease	Malignant neoplasm of breast	CENPF SPATA18 HLCS CLIP1 DES KCNA5 PRRC2A PDZD4 EVL INHBE DVL3 OCA2 SHROOM2 THOC5 USP54 LRRFIP1	1.66e-03	1074	190	16	C0006142
Disease	dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 measurement	SIGLEC5 SIGLEC14	1.79e-03	10	190	2	EFO_0801544
Disease	aspirin use measurement	HDAC9 CFDP1 CELSR2	2.03e-03	39	190	3	EFO_0007013
Disease	complement C1q tumor necrosis factor-related protein 1 measurement	CDH23 CELSR2	2.61e-03	12	190	2	EFO_0801493
Disease	nicotine dependence (implicated_via_orthology)	TRPC6 TRPC7	2.61e-03	12	190	2	DOID:0050742 (implicated_via_orthology)
Disease	granulins measurement	CDH23 CELSR2	2.61e-03	12	190	2	EFO_0008141
Disease	Calcium channel blocker use measurement	USP34 CHDH INSR ADRB1 CFDP1 FGF9	2.65e-03	213	190	6	EFO_0009930
Disease	resting heart rate	SPEG C19orf47 DES HABP4 MICAL2	2.84e-03	149	190	5	EFO_0004351
Disease	Vitiligo, response to rhododendrol	PPFIA3 MICAL2	3.07e-03	13	190	2	EFO_0004208, EFO_0010824
Disease	myeloid white cell count	HDAC9 USP34 TRPC6 CDH23 EHD4 ADRB1 WIPF2 TNS3 DNAH10 ZNF316 CHD7 SLC18A1 MICAL2 ZFHX3	3.12e-03	937	190	14	EFO_0007988
Disease	primary ovarian insufficiency (implicated_via_orthology)	USP17L1 USP17L18 USP17L3	3.25e-03	46	190	3	DOID:5426 (implicated_via_orthology)
Disease	reticulocyte count	USP34 HK1 INSR CLIP1 GGCX EHD4 ADRB1 PLEKHA7 USP3 TNS3 ARHGEF28 DNAH10 USP37 MICAL2 KIF1C	3.27e-03	1045	190	15	EFO_0007986
Disease	platelet component distribution width	HDAC9 SIGLEC5 TXK ADRB1 ANKDD1B PRRC2A MPP3 SUPT20H SIGLEC14 HABP4 BAZ2A ZNF333	3.75e-03	755	190	12	EFO_0007984
Disease	lung adenocarcinoma (is_implicated_in)	MCL1 PTPN13 ZFHX3	3.89e-03	49	190	3	DOID:3910 (is_implicated_in)
Disease	apolipoprotein B measurement	HK1 PSD STAG1 ADRB1 ZNF296 ANKDD1B GPSM2 DNAH10 CELSR2 SLC18A1 ZFHX3	3.96e-03	663	190	11	EFO_0004615
Disease	pulse pressure measurement	HDAC9 USP34 INSR MCL1 LUZP1 C11orf96 CFDP1 ADAMTS15 FGF9 PLEKHA7 VCL TNS3 TRMT12 COL6A3 DLGAP4 FBXL19 ZFHX4 ZFHX3	3.98e-03	1392	190	18	EFO_0005763
Disease	alcohol consumption measurement, high density lipoprotein cholesterol measurement	INSR MPP3 DR1 UBE3B CELSR2	4.06e-03	162	190	5	EFO_0004612, EFO_0007878
Disease	Autosomal Recessive Centronuclear Myopathy	SPEG MTMR14	4.10e-03	15	190	2	C3645536
Disease	Bell's palsy	LUZP1 SLC41A3 DNAH8 PKMYT1	4.33e-03	102	190	4	EFO_0007167
Disease	inflammatory biomarker measurement, YKL40 measurement	CENPF USP3 ARHGEF28	4.36e-03	51	190	3	EFO_0004869, EFO_0004872
Disease	5-oxoproline measurement	DNAH8 OPLAH	4.66e-03	16	190	2	EFO_0010988
Disease	idiopathic scoliosis (implicated_via_orthology)	DNAH10 KIF7	4.66e-03	16	190	2	DOID:0060250 (implicated_via_orthology)
Disease	alcohol drinking, high density lipoprotein cholesterol measurement	INSR MPP3 DR1 UBE3B CELSR2	4.74e-03	168	190	5	EFO_0004329, EFO_0004612
Disease	glucose-dependent insulinotropic peptide measurement	SLC41A3 RPH3AL ABCB9	4.86e-03	53	190	3	EFO_0008464
Disease	prostate carcinoma	TRIO GGCX DLGAP3 ADRB1 SUPT4H1 TNS3 COL6A3 RBM15 CHD7 BARX2 SHROOM2 ARHGAP6 ZFHX3	5.29e-03	891	190	13	EFO_0001663
Disease	triglycerides in medium VLDL measurement	MPP3 DNAH10 CELSR2	5.39e-03	55	190	3	EFO_0022155
Disease	Antithrombotic agent use measurement	HDAC9 CELSR2 ZFHX3	5.39e-03	55	190	3	EFO_0009925
Disease	coronary artery disease, factor VII measurement	HDAC9 STAG1 CFDP1 CELSR2	5.84e-03	111	190	4	EFO_0001645, EFO_0004619
Disease	Beta blocking agent use measurement	INSR ADRB1 FGF9 CELSR2	6.41e-03	114	190	4	EFO_0009929

Protein segments in the cluster

Peptide	Gene	Start	Entry
AAPLGKRTEEGRLST	nan	111	Q6ZR03
LANGRAGKRRPSRLV	ADRB1	301	P08588
VLAPGAGEQRRRAAK	ARSK	16	Q6UWY0
PNIGRGTGRREISSK	BDP1	816	A6H8Y1
DGSRRKPRLAASLQI	ADAD2	11	Q8NCV1
LEKERDRARVTGGIP	ASAP3	161	Q8TDY4
RLALSSRSGLERKPE	C19orf47	331	Q8N9M1
RGRGREGLAPQRKTT	BAZ2A	1566	Q9UIF9
RLRLSEELSGGRIKP	ACTR3B	346	Q9P1U1
LNKDGTPREGTRTKR	FGF9	166	P31371
SQKLGEVLERSRRLP	C8orf58	111	Q8NAV2
RSPEESLGGRRKRNV	CELSR2	161	Q9HCU4
RLRKVALAPGEGVSR	DENND1C	316	Q8IV53
TRLNGTAKGERRREP	DVL3	156	Q92997
RIITAIDQDKGRPRG	CDH23	256	Q9H251
GEGASRRGRRPKSEI	CHD7	2711	Q9P2D1
RGEAKARGESPGRIR	DLGAP4	126	Q9Y2H0
LLRDRDSGPKVTGNA	ADAMTS15	271	Q8TE58
VGLLRVKPGRGDRTR	ADAT1	281	Q9BUB4
RGADGPLRVSRGKTN	CHDH	181	Q8NE62
SGEKENRGGRRAVRP	FBXL19	361	Q6PCT2
ITRDRDSGRLKPALG	RAD51D	251	O75771
PIRDRRGSLEKSQGD	RBM15	701	Q96T37
SGLAELVAGKRRLPR	OCA2	26	Q04671
ERRGRSATGRAKEPL	TSPOAP1	1561	O95153
RRGLGVDSKPELQRV	FAM107A	56	O95990
LRPKGLDGARAERVL	SHMT2	386	P34897
GELTDLLNRGREPRA	MSGN1	176	A6NI15
ILRGGPLQDQKSRDA	ARHGEF28	1416	Q8N1W1
IGLQRTGSLPRKRGE	PHLDB3	386	Q6NSJ2
RGSLPDQKDLRLGSI	FBXO42	486	Q6P3S6
GRPTGGSTDRIQKLR	PARD3B	1016	Q8TEW8
DPLLRSAGKVRDINR	KIF14	51	Q15058
ARDGPGLRDRAKVLI	PCDHGA6	321	Q9Y5G7
KEPNAEGRRLSLTSG	PARP8	446	Q8N3A8
QLEKRPRVSEASRGL	KRBA1	726	A5PL33
EIDSSLNGVRPKLGR	GPSM2	391	P81274
PGRVKIDRSRAIRGE	MAP1A	481	P78559
SRKRLPDGLTRRGDI	MCM5	361	P33992
QRRKSLPARDGGFTL	MTMR14	411	Q8NCE2
PDLGGLEALRQREKR	FLYWCH1	481	Q4VC44
SGKLRIPAAQERDAG	HMCN2	746	Q8NDA2
QLSRRRSGLEEPGKD	PPFIA3	201	O75145
GRNDGVETIKSRLLP	SPATA18	66	Q8TC71
TSPEREGRRVNLTGK	HLCS	146	P50747
TDLQGRDGLLTVRKP	CDH24	311	Q86UP0
GGRRESQKERKSLPA	HABP4	86	Q5JVS0
ARLRALKRAGSPEVQ	HR	406	O43593
LKIRANEPGAGRARR	INHBE	221	P58166
RIRKILVDLSNPGGR	PLXNA1	456	Q9UIW2
GRRNPKTGLTLERVG	PDZD4	546	Q76G19
KLRRVQRPEDASGGS	EVL	231	Q9UI08
SVLRTLGSQKRARPE	DNAH8	2026	Q96JB1
GARVRRSIGRPELKN	PIR	21	O00625
GRRDNLAKLPTGTTL	POLG	626	P54098
QNLKRRPGSGTDGLR	FAM157C	206	P0CG43
GKLRQGSLLSPEEER	KIF7	1026	Q2M1P5
DLLNPKSRGSLRVRE	KIF1C	156	O43896
GVSRKSPLAEEGRLN	LARP6	391	Q9BRS8
DSPGILSGEKQRISR	EHD4	156	Q9H223
RRRGALPQESLKDAG	KCNK13	166	Q9HB14
ERGSSLRKDGPLDIR	METTL15P1	181	P0C7V9
KRQRLESAEGVLRPG	POLE	1291	Q07864
LPGVAEKSRERLIRN	EXOSC5	86	Q9NQT4
RPSRKRRSLGDVGNV	INSR	756	P06213
DVGLPGVSRARALRK	NOP14	51	P78316
RRDAPAGRKVGLIAA	RPL8	226	P62917
GAILNRLRDNKGTPR	HK1	391	P19367
RRKASSRLENLGIPE	DR1	101	Q01658
RKLPVDRIVGGRDTS	HPN	156	P05981
QPSKGGLLERTASRL	MVB12A	176	Q96EY5
RPRVFGDQRGLSQDK	HMCN1	1071	Q96RW7
RALAKERRNRPESGG	OTUD3	31	Q5T2D3
SSLIRQKREVREPGG	FGF11	6	Q92914
KLRQTRSLDPALIGG	ARHGAP6	31	O43182
ERLELGLGRERPAKA	MON1A	11	Q86VX9
LLRVKSVPGRRLADG	CPLANE2	201	Q9BU20
TEQELRARKAARPGG	ABT1	216	Q9ULW3
QSIPARKRRQGGLSL	CFDP1	56	Q9UEE9
LAEEPKRRGTASRGR	ESPL1	1411	Q14674
PGLDRGVQRKVSGSR	KCNA5	546	P22460
LEQPEGSRRKGITLT	C2CD2	656	Q9Y426
TDSPREGLRVKRGRL	CENPF	3081	P49454
GLGLRPESSQKAIRE	FRMPD2B	231	Q6IN97
ELRLSSPGQLKAARR	BARX2	6	Q9UMQ3
RNIFKRPLGSRIEEG	COL6A3	1321	P12111
LRGRGVPVKERSLDS	DLGAP3	921	O95886
LAAEVNRLKGREPTR	DES	136	P17661
KQGLPESGRVRAEER	LUZP1	1051	Q86V48
RLSPSSDGRREKGLA	HSF4	276	Q9ULV5
PRLRRGQSADKLGTG	MAST3	1216	O60307
GLTPLRGRGLRSQEK	LYRM1	91	O43325
LGPRGNSLKRLQEET	KHDRBS2	81	Q5VWX1
DRQGSEAKLSVGPLR	CNTNAP2	776	Q9UHC6
GPIRLKRDRSASGNS	CUZD1	536	Q86UP6
LPLGGGRDRKVRDLQ	HBEGF	51	Q99075
PLRGKDRGRERAVAS	HDAC9	126	Q9UKV0
RRAAGEGLLTLRAKP	EPS8L1	296	Q8TE68
QLDRKALGSARSPEG	GPRIN1	726	Q7Z2K8
SSLLGEGREQRPELR	GPRIN2	26	O60269
ETSRDKSRQGPRRGK	CCDC8	111	Q9H0W5
DLDQVRKRLGTGLSP	DNAH10	4216	Q8IVF4
VAELRRRLESNKPAG	CLIP1	526	P30622
VGSRGSLRVEERPEK	LRRFIP1	76	Q32MZ4
PGGRLLATEKEASAR	MCL1	31	Q07820
SRKALETLRRVGDGV	MCL1	206	Q07820
SAENGRGGRVLKPVR	MICAL2	1476	O94851
RSQAIRDRLRGKGLP	PTPN13	196	Q12923
STEGLQELKRRRGPA	nan	401	A6NNC1
LRAGLIPSKGFQERR	MPP3	281	Q13368
LEDRLPSTGVRDRKG	RPH3AL	221	Q9UNE2
VLLAVSRGTPNRERK	STK11IP	716	Q8N1F8
LGPGSNRKLRLEAST	PSD	141	A5PKW4
KGLLQSGQIPGRERR	SNRPA1	221	P09661
RRGITKAGERDKAPS	TEDC2	91	Q7L2K0
QRKGFPTEGERRQLL	MRM1	306	Q6IN84
RSGLRLEDAPKAQTG	OPLAH	641	O14841
RKRTLGQGERTGLPS	PLEKHA7	1091	Q6IQ23
EIPKRRRQRGSETGS	PRRC2A	1096	P48634
RTPNIDRLASGGVKL	STS	51	P08842
RVKPETQGRFRLLGD	SIGLEC5	81	O15389
PRIGGRRRFTAEQKL	SHROOM2	746	Q13796
VNRRTQKSGIGDRPL	SGO2	1201	Q562F6
GDEAQKRLRISFRPG	SLC12A1	51	Q13621
RGRLADKRTVALPAA	SAMD11	26	Q96NU1
TRQRRLDSCGKPGEL	SLC41A3	6	Q96GZ6
LKGAQERIDSLRRTG	PRRC1	306	Q96M27
LNRRSALARVGKVGP	WDR45	271	Q9Y484
KVTRGERPLRGERAT	PRR12	1746	Q9ULL5
PGTRRGLSAQEKAEL	TNS3	411	Q68CZ2
GRLPQGIVRELKSRG	SUPT4H1	91	P63272
GTFVQRRLKRGDADP	SLC6A20	576	Q9NP91
KRRSLGLGPGERVEV	SRBD1	961	Q8N5C6
PRAGEVSQRLQGLRK	SPTBN5	2221	Q9NRC6
IGVAKNSALGPRRLR	ABCB9	66	Q9NP78
RSLSRIPKREGLGEE	ANKDD1B	41	A6NHY2
DGDQERLISKPRVGR	AHNAK2	236	Q8IVF2
RGRGALARPVLTKEQ	CHTOP	201	Q9Y3Y2
AVTFPERRGDVRRKG	C11orf96	176	Q7Z7L8
KRIPRRGEIGLTSEE	NKAPL	316	Q5M9Q1
PRKQREFSGSDRGKL	XIRP2	2626	A4UGR9
ETGQAAVPSRKRRRG	nan	6	P0C880
LEKARRTRALLQPGD	PLEKHG5	406	O94827
PRALGAEDTDRRAKQ	USP17L3	391	A6NCW0
TRARERKGQFRAVGP	ZFHX4	2611	Q86UP3
IPSGRTVDKLEDRGR	TICRR	611	Q7Z2Z1
KAELISGPRQDSRIG	GGCX	21	P38435
KARRAREEGKLPSLG	nan	101	Q6ZSR3
QAGLLTTDPRVRERK	MRPS9	366	P82933
RQRLLRGGPEDGKVS	SPEG	2071	Q15772
RGPKDRARKLAEVGS	PKMYT1	146	Q99640
RRSSLPNGEGLQLKE	PPM1H	121	Q9ULR3
DRNPGLSKERVRASL	RNF34	241	Q969K3
NDLVRKRRLADLTGP	TMOD1	336	P28289
RRRKQGAGSLQELAP	SPEF1	116	Q9Y4P9
LEKRLGGLAPQRGSR	TNS4	256	Q8IZW8
KRLQDVGTPAARARA	TRPM2	776	O94759
RRGAADPVARKALTL	TMEM121	101	Q9BTD3
LRGKNGSDSETIRLP	SUPT20H	91	Q8NEM7
PRALGAEDTDRRAKQ	USP17L18	391	D6R9N7
GNLPGDARVSDLKRA	MTHFSD	311	Q2M296
ADLRRQGKGDSPEAR	VCL	446	P18206
RSGRPDVARELGKNL	TMDD1	136	P0DPE3
RKSPGEKSRIEAGIR	STAG1	51	Q8WVM7
GLKRNSERKTPEGRA	TOMM70	76	O94826
PRALGAEDTDRRAKQ	USP17L1	391	Q7RTZ2
SRRRKVVGLGVPRDG	nan	146	Q6ZUG5
GRELDAGRKPKLTRT	SOCS7	256	O14512
GQRAEPKATERGILR	ZNF333	56	Q96JL9
KREGSAVDPGKRRSL	YY1AP1	26	Q9H869
KAARRQVEGRRGPVS	TOPAZ1	76	Q8N9V7
GPDGVRRKCQTRRLE	TMEM81	66	Q6P7N7
PAVELRNGKTAGRRT	USP3	191	Q9Y6I4
RNILRPVGGKRVDSA	UBE3B	441	Q7Z3V4
KARDRLGNEGLIPSN	TXK	121	P42681
TPLRSGLLENRTEKR	USP37	191	Q86T82
QERLSRGGDAKSPVL	ZNF316	101	A6NFI3
EEFRGRLERTKSQGP	PIGO	806	Q8TEQ8
QRLAKRGRVSPDGTR	TRMT12	171	Q53H54
VLREKGRRLANRGPA	TRPC6	71	Q9Y210
SLGAPRRERKGEGVQ	USP34	1311	Q70CQ2
RRERKGEGVQLPASC	USP34	1316	Q70CQ2
ALGKPNRRIRRESTG	USP34	1446	Q70CQ2
GTAGQKERDRKTRPL	TCHHL1	401	Q5QJ38
QPKLSRDEQRGRGAL	WIPF2	26	Q8TF74
LKAEGTPGRRGAQRS	TMC2	41	Q8TDI7
AAGGEPRGRELRSQK	XPC	6	Q01831
TTKRRRPTLGVQLDD	THOC5	321	Q13769
VGPKDSRLSRDSLQG	SHE	96	Q5VZ18
RRQRKGEECSLPGLT	SULF1	731	Q8IWU6
RVKPETQGRFRLLGD	SIGLEC14	81	Q08ET2
LKQESRGRRLSPQTG	nan	221	Q8N7P7
APATRQKGRRDGEDL	TRIO	1611	O75962
GKRGIRRLIRGPAET	TWF1	331	Q12792
ILDLPRTGNRKASGS	ZNF789	71	Q5FWF6
SEGSLEKLVEQRGPR	ZNF34	151	Q8IZ26
TLREKGRRQAIRGPA	TRPC7	16	Q9HCX4
RGPSRGQGSEREELK	ZNF296	141	Q8WUU4
SGTGGEEPQRDKRLR	ZFHX3	2631	Q15911
KRSSGRVRRKGDEPQ	USP54	461	Q70EL1
LDAPQRLLKEGRASR	SLC18A1	6	P54219
GRSSGEKLSRPDLKR	ZBTB6	406	Q15916
QKELGLRNEREAPGT	KIAA1522	171	Q9P206
RFEPKRLGDSVRLGQ	ART5	166	Q96L15
SRGSRQPDGLLRKGL	N4BP3	36	O15049
KVRSLGGISPSEDRR	MYO9A	1291	B2RTY4